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ABSTRACT 
Since glucocorticoids first were discovered and then synthesized in the 1940s, 
they have revolutionized the treatment of a wide variety of medical conditions. 
Unfortunately, they also have a very large number of adverse effects in almost 
every organ system in the human body. Many of these adverse events have 
been studied, but in almost all cases chronic glucocorticoid use was the 
exposure of interest. But glucocorticoids are often used in short 'bursts' of a few 
days to weeks. There is little evidence as to whether these short bursts are 
dangerous. In this dissertation we focus on the adverse events of 'burst' 
glucocorticoid use to investigate whether these short courses have a meaningful 
risk on human health. We study three separate conditions in three different 
organ systems: osteonecrosis, which has long been known to occur from chronic 
glucocorticoid use; myocardial infarction which has more recently been 
implicated as a complication of glucocorticoid use; and upper gastrointestinal 
bleeding, which has long been recognized as an adverse effect of chronic 
glucocorticoid use but which has been somewhat forgotten recently. We find 
v 
evidence in each of these conditions that short bursts of glucocorticoids are 
associated with the onset of each of these three conditions. Unfortunately, 
despite the use of modern case-only study methods that eliminate between-
person confounding, we find it impossible to eliminate confounding, especially 
confounding by indication, as a source of the apparent positive association in at 
least two of these conditions. 
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GENERAL INTRODUCTION 
GLUCOCORTICOIDS 
Endogenous glucocorticoids (GCs) are hormones synthesized in the adrenal 
cortex.1 The predominant human GC, cortisone, has diverse functions in the 
human body and helps to regulate such activities as glucose and energy 
metabolism, cell growth and development, stress responses, neuronal function , 
and the control of inflammation. 1-4 
Synthetic GCs were first developed in the 1950s and 1960s, and were developed 
to not have the mineralocortioid effects of endogenous GCs.5 Like cortisone, 
synthetic GCs are 21-carbon steroids, but variations in their structures yield 
differences in rates of absorption, affinity for the glucocorticoid receptor (GR), 
rates of metabolism and clearance, and avidity to steroid-binding globulin .6 The 
latter binds to circulating GCs and protects against degradation; however only 
free GCs can interact with the GR.6 While endogenous cortisone binds to 
steroid-binding globulin with high affinity, most synthetic GCs do so with low 
affinity, making them more pharmacologically active in general.6 GCs are 
metabolized in the liver and excreted by the kidney. 7 
GCs exert their effect in humans by interacting with the GR in the cytosol of the 
cell. Upon binding with GC, the complex migrates to the cell nucleus where 2 
1 
complexes form a dimer which then interacts with GC response elements (GREs) 
of DNA to affect gene transcription and expression.2•3 
Adverse effects of glucocorticoids 
Because of the ubiquity of GC involvement in so many diverse biologic 
processes, the administration of supra-physiologic doses, while very effective in 
controlling various aspects of inflammatory processes, can and does cause a 
host of side effects in many different organ systems.6•8 GC administration has 
been clearly associated with skin atrophy, disturbed wound healing, skeletal 
growth retardation, muscle atrophy and myopathy, osteoporosis, cataract 
formation, glaucoma, mood swings, euphoria, depression, psychosis, 
hyperglycemia, hypertension, dyslipidemia, immunosuppression with increased 
risks for bacterial, viral , and fungal infections, and adrenal suppression when 
given for prolonged periods.6•8 And this list is likely far from complete. 
These adverse effects result from a host of different physiologic mechanisms that 
are far from completely understood and likely vary from condition to condition.6·8 
Development of GC analogues that selectively inhibit inflammation without 
interfering with other physiologic processes - so called selective GC receptor 
agonists (SEGRAs)- is of interest to many; however, despite active research no 
such compound is yet available. 9 
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'Burst' glucocorticoid use 
GC use is often not chronic. Short courses are often prescribed to 'settle the 
immune system' in cases of acute immune system activation. Conditions that 
prompt these short courses include, among many others, acute allergic 
reactions, asthma attacks, and gout attacks. Though there are few data that 
systematically examine how glucocorticoids are used, one recent study using 
National Health and Nutrition Examination Survey (NHANES) data suggested 
that around one third of GC prescriptions are for durations of less than 90 days. 10 
Even when considering longer prescriptions, practitioners will often try to limit 
exposure to the minimum time possible to accomplish a goal so as to minimize 
side effects as much as possible. 
The expected side effects of these short GC doses, often called 'bursts', is far 
from clear. Almost all the literature related to GC side effects studied persons 
that had used chronic GCs, often for chronic diseases such as chronic 
obstructive pulmonary disease (COPD) or rheumatoid arthritis (RA). There is a 
feeling among some practitioners that use of bursts, because they tend to be so 
short, are unlikely to result in measurable harm to individual patients. 11 ·12 But this 
assertion is supported by almost no actual data. Indeed there are many 
individual case reports of persons receiving short courses of GC treatment 
(though often of very high dose) who have had serious side effects.7·13-16 
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One of the major goals of this dissertation is to explore the effects of GC bursts 
and to better quantify what the risks are. We have chosen three conditions for 
this: osteonecrosis (ON) has long been associated with GC use; gastrointestinal 
bleeding (GIS) has been thought to be associated with GC use for some 
decades, but the risk is, perhaps, not widely recognized; and myocardial 
infarction (MI) is a relatively newly recognized potential risk. In none of these has 
there been any systematic examination of whether burst GC use imparts a 
meaningful risk to individuals. Finding that bursts can be used safely would be 
reassuring to clinicians, while finding an elevated risk of any of these conditions 
might compel clinicians to be more cautious in prescribing them or impel them to 
follow patients more closely for side effects after using them. 
UNITED STATES VETERANS AFFAIRS MEDICAL RESEARCH DATA 
We used linked data from the United States Veterans Affairs (VA) Health Care 
system. This is one of the largest health care systems in the United States, and 
because VA has been a pioneer in the development and implementation of a 
standardized electronic medical record system, VA is an important source of data 
for epidemiologic research. 
Health care data are extracted from the VA computerized health record, the 
Veterans Health Information Systems and Technology Architecture (VistA), which 
is used universally in VA hospitals and clinics and comprises the complete health 
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care record for each patient. Each VA practitioner enters data related to each 
patient encounter directly into VistA at the point of care in real time. We used two 
VistA extracts for this series of studies: the (ln)Patient Treatment File (PTF) and 
the Outpatient Clinic File (OCF). The PTF is essentially a record of each patient's 
acute inpatient hospitalizations, while the OCF is a record of all ambulatory 
encounters experienced by each patient. Both datasets contain demographic 
data (date of birth, gender, self-identified race and ethnicity), an assessment of 
VA "priority status" (a categorization of how the veteran qualifies for VA benefits 
and what benefits they are entitled to, based on conditions sustained or 
worsened while in military service, means testing, and other factors- see table 
a.4), and International Classification of Diseases, Ninth Revision, Clinical 
Modification (ICD-9-CM, subsequently ICD9) codes associated with each 
inpatient stay or ambulatory encounter, as well as the dates of each inpatient 
stay or outpatient encounter. 
Pharmacy data come from the Pharmacy Benefits Management (PBM) Services 
database maintained at BPM Services in Hines, IL. This database is a record of 
all prescriptions dispensed from VA pharmacies since the beginning of FY1999. 
Each record includes the drug product dispensed, VA medication class, ordering 
provider, number of units dispensed, dose per unit, dates ordered and 
dispensed, and form of administration (oral, intravenous, etc.). Prescribing 
instructions are also captured as a free text field. Since FY2003 inpatient 
5 
intravenous prescriptions are include in the data, and since FY2004 the data 
include oral 'unit doses' of medications given while a patient was hospitalized. In 
aggregate, these data provide almost complete records of veterans' use of 
medication (as usually there is a strong financial interest for veterans to use VHA 
as their primary medication source rather than outside pharmacies). 
These data sources were linked using unique patient identifiers to yield a record 
of patient visits and how these visits relate to drug initiation and 
discontinuation. 17-21 
THE SELF-CONTROLLED CASE SERIES STUDY DESIGN 
The self-controlled case series (SCCS) method is a case-only study design 
originally created to investigate whether some vaccinations can act as a 'trigger' 
for certain medical conditions.22 It has since been used to investigate whether 
some drug exposures can act as triggers for diseases or conditions.23-26 This 
design will be used for the second and third of the three studies that make up this 
dissertation. A detailed description of the method is beyond the scope of this 
dissertation and the interested reader is referred to the paper by Whitaker and 
colleagues for further details.22 
Briefly, cases are identified and each case's follow-up time is divided into periods 
of risk based on exposure to the potential 'trigger'. In the simplest form, the 
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exposure time is one risk period and the remaining time is the baseline (non-
exposed) period. The rate of events in the exposed period is compared to the 
rate of events in the baseline or non-exposed period giving the relative incidence 
(RI) for the event while exposed compared to baseline. Because the method 
compares the rates of events within individual persons, there cannot be between-
person confounding, and potential confounders that do not vary over time also 
cannot confound the exposure-event relationship. When there could be marked 
differences between those who are exposed and those who are unexposed in a 
traditional cohort study, the sees design is an appealing alternative when the 
conditions are appropriate (e.g. when investigating 'triggers' for acute conditions). 
Even~dependentexposure 
One of the underlying assumptions of the sees method is the assumption that 
events will not affect future exposure. Unfortunately this often is not true. For 
instance, children who develop intussusception may have a delay in getting the 
oral polio vaccine because polio vaccination can be a risk factor for 
intussusception and practitioners will therefore wait until children are fully 
recovered from an episode of intussusception before vaccinating them. Another 
example could be hospitalization for Ml and Ge use. Persons who are 
hospitalized for Ml may have hospitalization-related conditions (e.g., gout attacks 
which are often provoked by hospitalization) for which Ges are prescribed . In 
these cases, the event - hospitalization for Ml - is clearly affecting future 
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exposure in that because of the hospitalization there is an elevated risk of gout 
and therefore there is likely to be greater-than-usual GC use.22 
The effect of this event-dependent exposure is to change the baseline rate of the 
event. For instance, if all persons who are hospitalized for Ml and then get GCs 
are included in the baseline period, as they would be in a simple exposed/non-
exposed follow-up time model, the rate of hospitalization will appear to be 
elevated above the 'true' baseline. The elevated rate of Ml appears immediately 
prior to the exposure period . This would result in a biased (smaller) Rl when 
comparing the exposure period to the baseline period. 
Event-dependent exposure can be corrected by removing the period immediately 
prior to exposure (in which the rate of Ml is above the true baseline) from the 
baseline period.22 For instance, if it appears that an elevated rate of GC 
prescribing after hospitalization for Ml lasts for about a month, a one month pre-
exposure period can be added to the sees model. This removes the elevated 
rate of Mls from the baseline period and gives a less biased estimate for the 
exposure period vs the true baseline period (assuming no other sources of 
confounding or bias) . 
. The added pre-exposure risk period effect estimate must be interpreted with 
great caution. Note that it cannot be a causal measure of the exposure-outcome 
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relationship as exposure has not yet occurred during this period. It is probably 
better to simply view it as a 'correction factor' that makes the exposure estimate 
less biased, and not to attempt to give it any traditional meaning (i.e. a 
measurement of risk). 
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BURST GLUCOCORTICOID USE AND THE RISK OF OSTEONECROSIS IN 
US VETERANS 
INTRODUCTION 
Osteonecrosis (also called avascular necrosis, aseptic necrosis, and ischemic 
necrosis) is a condition in which the vascular supply to an area of bone is 
interrupted, thereby causing its death. This leads to pain, collapse of the affected 
bone, destruction of the contiguous joint (osteoarthritis), and significant functional 
disability. 
GCs have long been associated with the development of ON, though the means 
by which GC use contributes to the development of ON are not well understood. 1-
4 They may involve alterations in lipid metabolism producing either expansion of 
the fat element of bone marrow leading to increased bone marrow pressure and 
compromised blood flow, or fat embolization which directly blocks blood flow. 5-11 
Studies in varying populations have suggested that the risk of ON is highest with 
large daily GC doses within the first few months of chronic treatment. 12•13 There 
are, however, numerous anecdotal reports of ON occurring with very short GC 
courses. 1•14 Because GCs are now frequently used in a short 'burst and taper' 
for exacerbations of chronic diseases such as asthma, chronic obstructive lung 
13 
disease, and gout, a better understanding of the risks involved with these short 
courses is clearly desirable, yet no study has addressed this issue. 
In this study we aimed to evaluate whether 'burst' use of GCs is associated with 
an elevated risk of ON. 
METHODS 
Underlying cohort 
The underlying cohort for this case-control study is all patients enrolled in the VA 
healthcare system from FY1999 through FY2008 (October 1, 1998 to September 
30, 2008). Individual subjects could exit the cohort if they were lost to follow-up 
for a period of time (defined as no visits in 2 consecutive calendar years) and 
then re-enter the cohort later, when follow-up was re-established . 
Outcome (case) definitions and selection 
Case finding algorithm development 
We first developed and verified an algorithm to find potential cases of ON. 15 To 
create this algorithm, we first found all persons with outpatient codes for ON in 
the Boston VA healthcare system from FY1999 through FY2006 and examined 
the medical record of each . We determined whether these persons actually had 
ON (based on the definitions of Sugano and colleagues) , and if so determined 
the date of onset, which we defined as the approximate date of pain onset at the 
14 
affected joint. 16 We then tested a number of definitions for ON based on 
information found in administrative data sets. These included requiring a single 
code for ON in the administrative record from any source (inpatient or outpatient 
visits), requiring at least 2 codes, requiring a single code originating from an 
inpatient discharge summary, and each of these in combination with the 
requirement that no code for osteoarthritis (OA, not to be confused with ON; OA 
is often a consequence of longstanding ON) was present. 
We then calculated the positive predictive value (PPV) of each definition for both 
'confirmed' ON (disease was present at some point in time) and for 'incident' ON 
(disease began within 6 months of the first code). Finally, for each definition we 
calculated the number of medical records that would need to be reviewed to find 
100 cases of incident ON for each algorithm. 
Case finding 
For the final algorithm we used the definition requiring an inpatient ON code and 
no previous code for OA. We found all persons in the VA that met this definition 
between FY1999 and FY2008 and called these persons potential cases. 
In random order, we reviewed the medical record of each potential case and 
determined 1) whether ON was in fact present according to the definitions of 
Sugano and colleagues, and 2) whether the onset of symptoms appeared to be 
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within 3 months, 6 months, 1 year, or more than one year prior to the 1st ON 
code (which was the earlier of the first inpatient or outpatient code). 16 We 
reviewed records until we found 400 confirmed cases where symptoms began 
within one year of the first ON code (incident cases). This number was decided 
upon after an initial analysis of 200 incident cases that showed suggestive, but 
not statistically significant, results. 
For all cases, we recorded the site of ON (hip, knee/tibia, ankle/talus, foot/MTP, 
shoulder/humerus, wrist/scaphoid, jaw). After finding the first 200 cases (11 00 
potential cases had been reviewed) we also started recording the reasons for not 
including each potential case as a case. Reasons included that the case was 
'prevalent' (onset was clearly documented to be more than one year ago), likely 
to be prevalent (it appeared likely that onset was greater than one year ago), 
could have been prevalent (a date of onset more than one year ago was 
possible), the potential case was mis-coded (the case clearly should have been 
diagnosed as another condition and ON was coded in error), or the diagnosis 
was unclear (the actual diagnosis was unclear but did not appear to be ON). We 
also started recording the site of ON when ON was present but not incident. 
Further exclusions 
At this point, we had a collection of cases (and controls- see 'Control selection ' 
below) who had confirmed ON that occurred within the year prior to their first ON 
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code. However, these included GC non-burst users, GC burst users, and GC 
non-users. We therefore eliminated all those cases (and their corresponding 
controls) who had used GCs in a non-burst fashion (defined in the 'Exposure' 
section below). We were left with cases who were either burst GC users or GC 
non-users. 
We then further eliminated all cases (and corresponding controls) where the first 
diagnosis code for ON occurred within the first year of follow-up, and/or where 
there was a GC prescription within the first year of follow-up. This was done to 
eliminate those persons who might have had ON prior to enrolling in the VA 
system (outcome misclassification) and those who might have had GC 
prescriptions prior to enrolling (exposure misclassification). 
Control selection 
For each potential case identified we randomly matched up to 10 controls on VA 
site, sex, age group (20-29, 30-39. 40-49, ... , 80-89, > 90), calendar year of 
enrollment, and calendar year of the first ON code. Note again that controls were 
selected using potential cases, as at that time we were considering testing 
different ON case definitions; therefore as potential cases were eliminated, as 
described above, their matched controls were eliminated as well. Finally, all the 
above exclusions were applied to the remaining controls; i.e. we eliminated 
controls who were not either burst users or non-users, and those who had first 
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ON codes or first GC prescriptions within their first year of follow-up . Therefore 
throughout the study case and control matching was maintained, but in the final 
data set cases could have fewer than 10 controls. 
The incidence date for controls was assigned to be the incidence date for the 
matching case. 
Exposure 
We evaluated whether exposure to burst GCs was related to the development of 
ON using outpatient prescriptions for GCs. These included the following oral and 
intravenous GCs: betamethasone, budesonide, cortisone, dexamethasone, 
hydrocortisone, methylprednisolone, prednisone, prednisolone, and 
triamcinolone. We ignored prescriptions for intra-articular GCs as intra-articular 
GCs have limited systemic effects. Unfortunately we were forced to ignore 
possible intramuscular injections as well as it is impossible to differentiate intra-
articular and intramuscular prescriptions using VA prescription data. For this 
study, inpatient prescriptions were ignored, as were outpatient prescriptions for 
topical GCs. 
We defined a GC 'burst' as a prescription of less than or equal to 30 days with at 
lest 42 days between consecutive prescriptions. Persons who used GCs other 
than in a burst manner were excluded from the study. For cases, those who 
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used non-burst GCs were excluded along with their matched controls. For a 
control whose case was not excluded the control was simply removed from the 
case-control set. Cases and controls who had never used GCs were retained. 
Confounders 
Potential confounders were evaluated in the two years before the date of the 1st 
ON code in cases, and the matching date in controls. We looked for ICD-9 
codes indicating the presence of known potential confounders, including prior 
fracture and alcohol use. Prior fractures (codes 800-829) were sought only in the 
year prior to the 1st ON code, and could be at any site, and therefore were not 
necessarily at the site of ON. These data do not allow a detailed ascertainment 
of alcohol use so we used disease codes that would suggest heavy alcohol use. 
These included codes for alcohol dependence (303), alcohol abuse (305.0), 
excess blood alcohol level (790.3), alcoholic liver disease (571.0-571 .3), 
alcoholic psychosis (291 ), alcoholic cardiomyopathy (425.5), alcoholic 
polyneuropathy (357.5), and alcoholic gastritis (535.3). We took the presence of 
any one of these to indicate that the subject used alcohol heavily. Fracture and 
heavy alcohol use were coded as binary variables indicating use or no use in the 
prior one (fracture) or two (alcohol) years . 
Other conditions that could be associated independently with a risk of ON or that 
could be associated through GC use include both past and recent cancers, 
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autoimmune diseases, and respiratory diseases. Some cancers (140-209, 230-
234) include GCs as a component of therapy. Autoimmune diseases such as 
rheumatoid arthritis (714), systemic lupus erythematosus (710 .0), 
spondyloarthropathies (720), psoriatic arthritis (696.0) , so-called 'palindromic' 
rheumatism (719.3), vasculitis (710.1-710.9) and other connective tissue 
diseases (446.x) are often treated with high dose GCs, as are some respiratory 
diseases (490-496) especially chronic obstructive pulmonary disease (COPD, 
491.xx, 492.xx) and asthma (493.xx) . We therefore controlled for each of these. 
Presence of any of the conditions was indicated by a binary variable for presence 
or not within two years. 
Use of bisphosphonate (BisP) medications has been suggested to be a cause of 
ON. 17·18 These medications are often given for osteoporosis (not to be confused 
with ON) but may also be linked to the development of ON of the jaw and other 
sites. 17•18 As a further complication , GC use is a well recognized cause of 
osteoporosis and therefore there is likely to be elevated BisP use among GC 
users. Therefore we controlled for both the presence of osteoporosis (733.0) and 
BisP use in the prior two years (binary variables, use vs. no use). 
Analysis 
We present proportions of persons with given demographic characteristics, 
confounders, and use of GCs and BisPs. We used conditional logistic regression 
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to calculate the odds ratios of ON, compared to no GC use, for 1) the number of 
burst GC prescriptions, 2) the total dose of GC taken prior to ON onset, and 3) 
the last time a GC was used. 
The main analyses used the date of the 1st ON code as the index date. 
However, this method could result in exposure misclassification as there is 
usually a lag between disease onset and the time when the disease is identified 
by a health care provider. Therefore, we repeated this analysis using only those 
cases and corresponding controls where symptom onset was clearly 
documented in the clinical notes to have occurred within 1 year, 6 months, and 3 
months of the first ON code, and using this revised index date (i.e. before the first 
ON code) as the index date in each analysis. Each analysis evaluated GC use 
only until the revised index date. The analysis using only those cases where 
symptom onset was within 3 months should have the least exposure 
misclassification; unfortunately it also had the fewest number of cases as 
diagnosis was frequently delayed longer than 3 months. 
RESULTS 
Case finding algorithm 
In our study to determine a case finding algorithm we found 87 potential cases of 
ON within the Boston VA Healthcare System from FY1999 through FY2006 
(Table 1.1).15 Most subjects were men (92%), and the age range was 21 to 92. 
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Of these, 81 were confirmed as cases of ON. The most common ON site was 
the femoral neck (85% of confirmed cases). Only 15 cases were classified as 
being incident (pain occurring within 6 months of the first ON code) . Of these 
incident cases, 93% were in the femoral head. 
Table 1.1: ON cases in the Boston VA (FY1999-2006) 
Number of potential cases 
Ages (years) 
Women 
Sites (confirmed cases) 
Femoral Head 
Humerus 
Talus 
Carpal navicular 
Other foot/ankle 
Sites (incident cases) 
Femoral Head 
Humerus 
Talus 
Carpal navicular 
Other foot/ankle 
87 
21 - 92 
7 (8%) 
81 (85% of potential cases) 
71 (88%) 
15 
4 (5%) 
2 (2%) 
2 (2%) 
2 (2%) 
14 (93%) 
0 
0 
0 
1 (7%) 
The PPVs for confirmed cases for all the administrative definitions of ON were 
generally very good (76% to 1 00%) (Table 1.2). Unfortunately the PPVs for 
incident ON cases were universally poor (17% to 46%). We felt that this 
precluded the possibility of using only administrative data to identify incident ON 
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cases: all potential cases would therefore need to be confirmed by verification in 
the medical record. 
Using an administrative definition of at least one ON code arising from an 
inpatient visit in addition to excluding persons who had prior codes for OA, we 
determined that for every 100 cases we reviewed we should be able to identify 
46 cases of incident ON (using the definition that symptoms occurred within 6 
months) (Table 2). 
Table 1.2: Characteristics of ON case definitions using Boston VA data 
(FY1999-2006) 
Number of PPVfor Number of Number of Definition Using 
records confirmed PPV for records needing incident ON Administrative 
meeting ON incident review for every cases Data (prevalent ON 1000 with any ON expected after definition 
and incident) code review 
At least 1 ON code 87(100%) 90% 17% 1000 170 
More than 1 ON 85 (98%) 92% 18% 980 176 
code 
At least 1 inpatient 47 (54%) 100% 23% 540 124 ON code 
(At least 1 ON 
code) and (no prior 25 (29%) 76% 24% 290 70 
codes for OA) 
(At least 1 inpatient 
ON code) and (no 13 (15%) 100% 46% 150 69 
prior codes for OA) 
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Case finding 
Using the administrative ON definition above we identified 6207 potential cases 
of ON from FY1999 through FY2008 in national VA records. After randomly 
reviewing an initial 1100 potential cases we found the number of projected 
incident cases was overly optimistic; we were able to confirm only 200 incident 
cases where symptom onset appeared within 1 year of the 1st ON code. After 
excluding those cases where the first ON code and/or the first GC prescription 
was within the first year of follow up (as well as their matched controls and other 
controls meeting this definition), we were left with 172 cases and 1521 matched 
controls. Preliminary analyses of these data showed wide confidence intervals 
despite suggestive point estimates in all analyses. We therefore elected to 
continue case finding until 400 cases were identified. 
We screened a total of 2191 potential cases to find 400 cases of ON with 
symptoms confirmed to have begun within the year prior to the 1st ON code 
(Figure 1.1 ). Of these, 215 had symptom onset within 6 months of the first code, 
and 129 had symptom onset within 3 months. 
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Figure 1.1: ON case and control flow 
4fOO cases of ON 
(FY98-fY08) 
' 
.. 
119 with index date In 1st year I 
17 with GC use In I st year I 
162 non-burst GC users I 
j112cases of ON j +-------------+ 1284}0 controls I 
I J7 with index date in 1st year I .J 
I n with GC use in I st year I ...-
160 non-burst GC users I 
L 
3053 cases and controls 
•3241 burst GC prescriptions 
..-
' 
274'1 controls 
•2658 discrete persons 
•83 are controls for 2 cases 
We only documented the reasons for exclusion in the last 913 potential cases 
(Table 1.3). 531 potential cases were cases of ON but were excluded because 
symptom onset was definitely or likely to have been more than 1 year before the 
1st ON code; 382 potential cases were either not ON (miscoded) or the diagnosis 
was uncertain. 
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In the 531 excluded potential cases who had 'prevalent' ON, the majority of 
cases were in the femoral neck (457, 86.1%) (Table 1.3). Other sites are shown 
in table 1.3. In the 400 identified incident cases, the majority again occurred in 
the femoral neck (91.5%) with the frequency in other sites shown in the table. 
Table 1.3: ON sites in included and excluded cases, and reasons for 
exclusions 
Sites of ON in incident ON cases N =400 % 
Femoral head 366 91.5 
Humerus I shoulder 9 2.3 
Tibial plateau I knee 8 2.0 
Wrist I scaphoid 5 1.3 
Jaw 4 1.0 
Ankle I talus 4 1.0 
Toe I foot 3 0.8 
Finger I hand 1 0.3 
Sites of ON in prevalent ON cases N = 531 % 
(not including incident cases) 
Femoral head 457 86.1 
Humerus I shoulder 14 2.6 
Tibial plateau I knee 9 1.7 
Jaw 9 1.7 
Ankle I talus 9 1.7 
Wrist I scaphoid 19 3.6 
Toe I foot 14 2.6 
Finger I hand 0 0 
Reasons for exclusion as a case N = 913 % 
Prevalent I likely prevalent 531 58.2 
Miscoded I unclear 382 41 .8 
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Main results 
After excluding those cases, corresponding controls, and other controls whose 
first ON code and/or first GC prescription occurred within the 1st year of follow-
up, and after limiting the cases and controls to burst GC users and GC non-users 
(i.e. excluding chronic GC users) we were left with 312 cases and 2741 matched 
controls (3053 subjects in total) (Table 1.4). There were 2658 discrete controls 
- each serving as a control for a single case - with 83 persons serving as a 
control for 2 cases each. The majority of subjects (97.5%) were men. The mean 
age of cases was 52.8 years (sd 9.7) and the median age was 52.2. The age 
distribution is given in table 1.4. The majority of cases (93.6%) and controls 
(97.6%) never received a burst GC prescription, and those who did most often 
received a single prescription (4.2% and 2.0% of cases and controls 
respectively) . No case or control received more than six burst prescriptions. 
2.4% of cases received a bisphosphonate, 6-fold more than controls (0.4%) 
(Table 1.4). Potential confounders were distributed as would be expected, with 
ON cases having a larger proportion of traditional risk factors for ON including 
prior fractures (10.3% vs. 2.2%), heavy alcohol use (16.7% vs. 3.4%), recent and 
past cancers (12.2% vs. 3.9% and 8.0% vs. 2.0%), autoimmune diseases (2.6% 
vs. 0.4%), and respiratory diseases (18.0% vs. 3.1 %). Of interest, ON cases 
also had a higher proportion of persons with osteoporosis (2.2% vs. 0.2%). 
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Table 1.4: Characteristics of ON cases and controls 
cases (ON) controls total 
N 312 2741 3053 
men(%) 299 (95.8) 2679 (97.7) 2978 (97.5) 
age distribution (%) 
20-30 3 (0.1) 2 (0.1) 5 (0.2) 
30-40 16(5.1) 89 (3.3) 105 (3.4) 
40-50 40 (11 . 7) 302 (11 .0) 342 (11 .2) 
50-60 126 (40.4) 1175 (42.9) 1301 (42.6) 
60-70 90 (28.9) 839 (30.6) 929 (30.4) 
70-80 28 (9.0) 258 (9.4) 286 (9.4) 
80-90 8 (2.6) 67 (2.4) 75 (2.5) 
> 90 1 (0.3) 9 (0.3) 10 (0.3) 
N of GC prescriptions(%) 
none 292 (93.6) 2675 (97.6) 2967 (97.2) 
1 13(4.2) 55 (2.0) 68 (2.2) 
2 3 (1.0) 6 (0.2) 9 (0.3) 
3 3 (1.0) 1 (0.0) 4 (0.1) 
4 1 (0.3) 3 (0.1) 4 (0.1) 
5 0 0 0 
6 0 1 (0.0) 1 (0.0) 
ever received a BisP (%) 8 (2.4) 12 (0.4) 20 (0.7) 
comorbidities (%) 
prior fracture 42 (10.3) 60 (2.2) 92 (3.0) 
heavy EtOH use 52 (16.7) 92 (3.4) 144 (4.7) 
osteoporosis 7 (2.2) 4 (0.2) 11 (0.4) 
recent cancer 38 (12.2) 107 (3.9) 145 (4.8) 
past cancer 25 (8.0) 55 (2.0) 80 (2.6) 
autoimmune diseases 8 (2.6) 11 (0.4) 19 (0.6) 
respiratory diseases 56(18.0) 86 (3.1) 142 (4.7) 
After adjustment, the potential confounders were associated with an elevated risk 
of ON roughly as expected: a history of heavy alcohol use imposed an a 5.3-fold 
risk (3 .6, 8.0) of ON , prior fractures a 3.8-fold risk (2.3, 6.2), recent cancer a 3.3-
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fold risk (2.3, 6.2) , and bisphosphonate use a 4.2-fold risk (1 .5, 12.0). Of 
interest, a history of osteoporosis imposed an 11 .3-fold increase in risk (2.6, 
48.2) of ON, but this estimate was based on a small number of persons with 
osteoporosis. 
One burst GC prescription was non-significantly associated with a 1.6-fold risk of 
ON (Table 1.5). Two or more prescriptions were associated with an increasing 
risk of ON with 2 prescriptions imparting a 5-fold risk and 3 or more prescriptions 
an 8.5-fold risk. The 95% confidence intervals for these risks excluded one. As 
expected , the cumulative GC dose was also associated with ON risk: 1-30 days 
total GC use doubled the risk, and 31-90 days elevated the risk by almost 9-fold . 
We had no cases who were using GCs at the time of the first ON code, and only 
one control using GCs at the equivalent time. Few cases and controls used GCs 
within a year of the first ON code. Most cases and controls last used GCs two or 
more years prior to the first ON code, and interestingly there was still an 
increased risk of ON in this group (OR 2.2). 
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Table 1.5: Main results: Risk of ON using different definitions of GC use 
Cases Controls Unadjusted 95%CI Adjusted 95%CI 
OR OR 
Never used a GC (ref) 312 2741 1 (ref) 1 (ref) 
No. of GC prescriptions 
1 13 55 2.1 1.0, 4.1 1.6 0.8, 3.5 
2 3 6 4.5 1.0, 19.6 4.8 1.0, 24.8 
3-6 4 5 8.1 2.2, 30.6 8.6 2.1, 35.2 
Test for trend: p = 0.0003 
Total GC use (days) 
1-30 days 17 61 2.4 1.3, 4.5 2.0 1.0, 3.9 
31-90 days 3 5 6.0 1.4, 25.3 8.8 1.9, 40.6 
Test for trend : p = 0.0012 
Last use of a GC 
Current 0 1 
1-90 days prior 3 5 5.2 1.2, 23.0 3.9 0.7, 21 .5 
91-180 days prior 1 4 2.7 0.3, 24.8 1.0 0.1,18.5 
181-365 days prior 2 5 2.0 0.2, 18.4 2.8 0.3, 27.0 
366-730 days prior 3 13 2.1 0.6, 8.0 3.0 0.8, 11 .3 
> 730 days prior 11 28 2.7 1.3, 5.7 2.2 1.5, 12.4 
Test for trend: p = 0.0090 
Sensitivity analyses 
Moving the index date to a year prior to the 1st ON code (to limit exposure 
misclassification) resulted in findings that were broadly similar to the primary 
analysis (Table 1.6). There continued to be evidence that remote use of GCs 
still imposed an elevated risk of ON. 
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Table 1.6: Sensitivity analysis: Index date for ON 1 year prior to date of 1st 
ON code 
Cases Controls Unadjusted 95%CI Adjusted 95% Cl 
OR OR 
Never used a GC (ref) 312 2741 1 (ref) 1 (ref) 
No. of GC prescriptions 
1 9 42 2.0 0.9, 4.4 1.8 0.8, 4 .1 
2 5 6 7.7 2.2, 27.4 7.1 1.9, 27.4 
3-6 0 3 
Test for trend: p = 0.0083 
Total GC use (days) 
1-30 days 13 48 2.4 1.2, 4.8 2.2 1.1, 4 .5 
31-90 days 1 3 3.3 0.3, 31.9 5.5 0.4, 69.9 
Test for trend: p = 0.0127 
Last use of a GC 
Current 0 0 
1-90 days prior 1 5 2.2 0.2, 20.3 3.0 0.3, 28.3 
91-180 days prior 0 4 
181-365 days prior 2 4 5.1 0.9, 28.0 6.5 1.2, 36.0 
366-730 days prior 5 17 2.6 0.9, 7.2 1.8 0.6, 5.4 
> 730 days prior 6 21 2.6 1.0, 6.8 2.5 0.9, 6.9 
Test for trend: p = 0.0201 
Limiting the analysis to those cases whose symptoms began within 180 days 
(N=215) and 90 days (N=129) of their first ON code again resulted in similar 
results (Tables 1.7 and 1.8). 
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Table 1.7: Sensitivity analysis: Index date for ON 6 months prior to date of 
1st ON code 
Cases Controls Unadjusted 95%CI Adjusted 95%CI 
OR OR 
Never used a GC (ref) 215 1896 1 (ref) 1 (ref) 
No. of GC prescriptions 
1 7 31 2.1 0.8, 5.1 1.9 0.8, 5.2 
2 3 6 4.9 1.0, 22.6 4.3 0.8, 22.7 
3-4 2 2 10.5 1.5, 75.0 9.8 1.3, 76.6 
Test for trend: p = 0.0026 
Total GC use (days) 
1-30 days 10 37 2.5 1.1, 5.4 2.3 1.0, 5.3 
31-90 days 2 2 10.3 1.4, 73.7 15.0 1.7, 128.3 
Test for trend: p = 0.0030 
Last use of a GC 
Current 0 0 
1-90 days prior 1 0 
91-180 days prior 0 1 
181-365 days prior 1 6 1.7 0.2, 15.4 2.8 0.3, 24.5 
366-730 days prior 3 11 2.8 0.8, 10.2 3.5 1.0, 12.6 
> 730 days prior 7 21 3.3 1.3, 8.3 2.5 1.0, 6.7 
Test for trend: p = 0.0115 
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Table 1.8: Sensitivity analysis: Index date for ON 3 months prior to date of 
1st ON code 
Cases Controls Unadjusted 95% Cl Adjusted 95%CI 
OR OR 
Never used a GC (ref} 129 1127 1 (ref) 1 (ref) 
No. of GC prescriptions 
1 4 25 1.8 0.6, 5.4 1.7 0.5, 5.6 
2 3 4 10.3 1.6, 65.0 11 .8 1.7, 84.7 
3-4 2 2 10.3 1.4, 73.6 10.3 1.3, 79 .1 
Test for trend: p = 0.0012 
Total GC use (days) 
1-30 days 7 29 2.7 1.1, 6.6 2.6 1.0, 6.9 
31-90 days 2 2 10.8 1.5, 77.8 16.1 1.9,136.7 
Test for trend: p = 0.0028 
Last use of a GC 
Current 0 1 
1-90 days prior 0 2 
91-180 days prior 0 0 
181-365 days prior 1 4 2.7 0.3, 24.3 4.6 0.5, 44.7 
366-730 days prior 1 7 1.6 0.2, 12.9 2.2 0.3, 18.4 
> 730 days prior 7 17 4.5 1.7, 11 .7 4.1 1.5, 11.6 
Test for trend: p = 0.0047 
DISCUSSION 
Interpretation 
Our results show that even short bursts of GCs may increase the risk of ON. 
Though in our main analysis one burst was non-significantly associated with an 
elevated risk of ON, there is a strong trend of increasing risk with more bursts, 
and it is likely that our study was simply underpowered to show the roughly 1.5 
fold risk of ON of a single burst. This finding was robust even when we tried to 
limit exposure misclassification by analyzing only those cases with symptom 
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onset within 180 and 90 days of the 1st ON code and reassigning the index 
dates. 
Our results also confirm those from previous studies showing that total 
cumulative dose of GCs is a risk factor for ON. 12 We here show, however, that 
that exposure need not be chronic to increase the risk of ON. 
This study also brings other findings to light. There are very few, if any studies, 
of ON in a general population database (which VA is admittedly not), or a non-
surgical setting. In this study, we confirm the impression that the vast majority of 
ON cases occur in the femoral head (about 90%) with the remaining 10% spread 
among the shoulder, knee, wrist, ankle, fingers, and toes. Our findings also 
suggest that ON of the jaw, a site of increasing concern over the last several 
year, occurs at a similar rate to other non-hip sites. 
A number of previously known risk factors for ON are confirmed by our data, 
including heavy alcohol use, and prior fracture (though we did not attempt to 
confirm that prior fractures occurred at the same site as the site of ON) . 
However, our analyses suggest a few new risk factors that have not been 
previously identified. These include prior bisphosphonate use and/or 
osteoporosis. (As bisphosphonate use could be correlated with the presence of 
osteoporosis, it is difficult to be sure whether one, the other, or both is actually 
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associated with ON: some studies have suggested that bisphosphonate use is 
associated with ON, while at least one study suggested that OP could also be a 
risk factor for ON.) 17-19 The fact that osteoporosis appears to be such a strong 
risk factor (a roughly 1 0-fold risk) cannot therefore be further interpreted at this 
time. 
A recent malignancy as a risk factor for ON is also a somewhat new finding that 
cannot be well interpreted in our study as the possibility that chemotherapeutic 
medications are the actual reason for the elevated risk is high. 
Results in context 
Though the literature is replete with reports that strongly suggest that chronic GC 
use is a risk factor for ON, there is very little data concerning what the risk of 
short courses is.2•4•13·17·20-24 While published case reports have suggested that 
short courses might be associated with ON, many of these cite episodes where 
very high doses of GCs, often IV, were used.1.3·25-27 There is very little if any data 
regarding short courses of oral GC use in doses routinely used in outpatient 
clinical practice. Many practitioners assume that short courses cannot induce the 
physiologic changes necessary to lead to ON.28 Our results suggest that this 
assumption is mistaken. Though the risk of ON is almost surely lower with short 
oral courses, the risk should not be ignored, especially as our results show that 
the risk increases with recurrent treatment and with higher cumulative dose. 
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There are also data from studies of GCs in other conditions that suggest that the 
physiologic effects of GCs can be very long lasting - on the order of months if 
not years- after discontinuation.29 This is supported in our data as well, where 
persons who have not used GCs for one or even two years still appear to be at 
risk of ON. 
Limitations 
Confounding by indication - in this case the possibility that the underlying 
condition for which the GC is prescribed rather than the GC itself is causing ON 
- is always a concern in pharmacoepidemiologic studies. However, we think 
that this is unlikely to entirely explain our results. The persons in this study are 
persons who do not chronically use GCs. Transient conditions that could cause 
GCs to be prescribed and could also cause ON are not impossible; however, we 
are unaware of conditions that could fulfill this requirement. 
One possible risk factor that could be associated with ON, which we were unable 
to control for, is smoking, as systematically collected information on this was not 
present in our data. As smokers are at risk of COPD and resultant exacerbations 
that are often treated with GCs, it's possible that this could confound our findings. 
Based on our initial study of ON in the Boston VA, we had expected that we 
would find considerably more cases than we actually found. It could be that 
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Boston is a referral center and therefore saw more cases of ON that had been 
correctly coded. Regardless, the smaller than expected number of cases 
impeded our efficiency in finding enough cases for this study. The relatively 
small number of cases we finally used could render our results susceptible to 
random effects. It could also affect our evaluation of confounding , as some 
confounders were very sparse after multiple levels of stratification. 
As all cases of ON were confirmed by examination of clinic records, it is unlikely 
that outcome misclassification could explain our results; in fact, the results of an 
analysis including all potential cases (data not shown) suggested that we 
successfully reduced bias due to outcome misclassification by limiting our main 
analysis to confirmed cases. The 'cushion' periods we designed into our study 
as well as our sensitivity analyses were used to minimize exposure 
misclassification. In the latter case, our sensitivity analyses were consistent with 
our main results. However, because it is very difficult to ever know exactly when 
a case of ON begins, it's difficult to entirely rule out exposure misclassification as 
a source of bias. 
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Conclusion 
In conclusion, we believe our results support the hypothesis that short bursts of 
GC use increase the risk of ON. 
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THE SHORT TERM RISK OF MYOCARDIAL INFARCTION ASSOCIATED 
WITH BURST GLUCOCORTICOID USE IN US VETERANS 
INTRODUCTION 
Glucocorticoids (GCs) are commonly used medications that mimic the effects of 
endogenous corticosteroids. They are highly effective anti-inflammatory agents 
that have revolutionized many aspects of medical practice; indeed their discovery 
lead to the Nobel Prize for their discoverers, Kendall, Reichstein, and Hench, in 
1950.1 Unfortunately a host of serious and common side effects accompany 
their use and can lead to major medical complications. 
One hypothesized side effect is the development of cardiovascular disease 
(CAD) and an elevated risk of myocardial infarction (MI) . There are numerous 
rationales for thinking that GC use could lead to CAD. These include noticeable 
adverse effects on blood pressure, lipid levels, and insulin sensitivity, and most of 
these effects occur very soon after patients start taking the medication. 2-9 
Several epidemiologic studies have now suggested that chronic GC use is 
indeed associated with an elevated risk of Ml. 10-12 However, our own 
unpublished research has shown that GC use is often intermittent and that many 
of those receiving GCs do so for only short periods of time. The side effects of 
these short courses of medication have not been investigated; indeed standard 
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epidemiologic methods are imperfectly designed to investigate the effects of 
these short GC courses. 
Therefore, we designed a self-controlled case series (SCCS) study to investigate 
whether short courses ('bursts') of GC use could act as a 'trigger' for MI. This 
method is better suited to this question than standard epidemiologic study 
designs and has the added advantages that, as the analysis occurs within 
subjects rather than between subjects, confounding by between-subject factors, 
such as the presence of chronic diseases or chronic drug use, should be 
controlled for better than in most published studies. 
METHODS 
Study design 
This was a self-controlled case series study as described in the General 
Introduction. This design eliminates between-person confounding and time-
invariant confounding within individuals. It is especially suitable for studies of 
'triggers' of acute events as here, where short term use of GCs may act as a 
trigger for MI. 
GC burst cohort 
The underlying cohort is those veterans who have received only burst GCs within 
the United States Veterans Affairs (VA) healthcare system, defined as follows: 
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We first took those persons who had ever received, as an outpatient, either an 
oral or an IV prescription of any of the following GCs: betamethasone, 
budesonide, cortisone, dexamethasone, hydrocortisone, methylprednisolone, 
prednisone, prednisolone, and triamcinolone. We limited this group to those who 
had received only burst prescriptions. We defined a burst prescription as one of 
30 days or less, and for which there was at least 6 weeks (42 days) before and 
after free of any other GC prescription. 
Individual subjects could exit and re-enter the burst cohort. For example, if a 
subject entered the VA, was followed for some years, was lost to follow-up 
(defined as less than 1 visit in 2 consecutive calendar years), and then re-
entered the VA for another period of years, both periods could be included in the 
follow-up time if the person otherwise met the criteria for burst use. 
Case ascertainment 
Within this cohort, we identified persons who had been hospitalized for a first MI. 
This was defined as an ICD9-CM code for Ml (41 O.XX but excluding 41 O.X2 
which codes for subsequent care of an Ml) in the first or second position of the 
discharge summary. This definition has been used in many studies of Ml risk 
factors and has been validated in multiple databases including VA. 12-18 For this 
analysis the burst cohort was limited to those persons who had an Ml by this 
definition. 
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Further inclusion criteria 
To limit exposure misclassification, after finding those subjects in the burst cohort 
who met the Ml definition, we excluded persons who could have received a GC 
during a previous hospitalization. From FY2004 through FY2008 VA Pharmacy 
Benefits Management (PBM) data contains a complete record of inpatient drug 
administration. Therefore we identified whether each individual had ever 
received a GC while an inpatient, and if they had done so within 6 months of the 
Ml admission, they were excluded from the analysis cohort for this study. 
For FY1999 through FY2003 PBM inpatient drug administration records are not 
complete; therefore during this time period if a subject had been hospitalized 
within the 6 months prior to the Ml admission they were excluded from the 
analysis cohort since we could not tell whether they might have received a GC 
(which are often prescribed to inpatients). 
To further limit exposure misclassification , we excluded persons whose first burst 
GC prescription occurred during the first year of their follow-up as they could 
have received a GC from another source prior to their VA enrollment. Similarly, 
we excluded persons who had their 'first' Ml within their first year of follow-up as 
this could have represented a recurrence that was not documented in VA 
records. 
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Exposure definitions 
GC bursts are often given as a 'burst and taper' with the initial dose being high 
but then falling over subsequent days. While VA records can capture this 
complexity when a prescription is entered, the feature is not used with 
consistency by prescribers; therefore it is often difficult to know exactly what the 
prescriber intended and it is not infrequent that the number of tablets dispensed 
is not the same as the number of day~ prescribed. For example, the prescriber 
could intend an eight-day prescription comprised of 20mg daily for 2 days, 1 Omg 
daily for 2 days, 5mg daily for 2 days and 2.5mg daily for 2 days. While this 
might be recorded as such in the record, it might also be recorded only as 15 
5mg tablets to be used over 8 days: the patient would take 4 tablets each of the 
first two days, 2 the next 2, 1 the next 2, and half a tablet on each of the last 2 
days. We tried to account for some of this complexity as detailed below, but 
ultimately some assumptions needed to be made. 
Methylprednisolone and prednisone 'dose packs' comprise 21 tablets of 4mg and 
5mg of each drug, respectively, meant to be taken over 6 days: 6 tablets on day 
one, 5 tablets on day two, 4 tablets on day three, 3 tablets on day four, 2 tablets 
on day five, and 1 tablet on day six. In VA dose-pack prescriptions can be 
recorded as a 1-day prescription, a 6-day prescription , a 21-day prescription 
(because 21 tablets are dispensed), or (default) a 30 day prescription (the 'dose 
pack', however, is the clearly identifiable 'unit' of the prescription). It is often not 
46 
clear whether prescribers mean for individual patients to take the 'pack' as 
intended by the manufacturer, or whether they are using a convenient package to 
prescribe 5mg tablets. We assumed that all 'dose pack' prescriptions were used 
as meant by the manufacturer and converted all prescriptions to 21 tablets for 6 
days, with average daily dose of either 14mg methylprednisolone or 17.5mg 
prednisone. This could underestimate the length of these prescriptions; however 
the total dose of GC over the whole prescription would remain the same, and 
each prescription would still qualify as a burst. 
In cases where the number of tablets was an integer multiple of the days 
prescribed (e.g. 20 5mg tablets for 10 days, 30 1 Omg tablets for 10 days), we 
assumed the intended dose was the multiplier times the dose of the tablet (here 
2 X 5mg = 1 Omg daily for 10 days, 3 X 1 Omg = 30mg daily for 10 days). To save 
money VA will often have patients cut tablets in half, so where the number of 
tablets was half the number days prescribed (e.g. 3 1 Omg tablets for 6 days), we 
assumed the intended dose was 0.5 times the tablet dose (here 0.5 X 1 Omg = 
5mg daily for 6 days). 
Where the number of tablets prescribed was smaller than the number of days 
prescribed (e.g., 7 tablets for 30 days) and did not meet the above criteria, we set 
the length of the prescription equal to the number of tablets (here 7 days instead 
of 30). As 30 days is often the default length of prescriptions for VA, 
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prescriptions with this number of tablets were frequent (34.59% of all GC 
prescriptions) and we often reset the prescription length. Likewise in cases 
where the number of tablets was larger than the number of days and did not 
meet the above criteria (e.g., 8 tablets for 1 day), we set the length of the 
prescription to the number of tablets (here 8 days instead of 1 ). 
Taking into account these changes, average daily doses for each GC 
prescription were calculated as: (strength of the tablets in mg) X (number of 
tablets dispensed) + (prescription length in days). All doses and average daily 
doses were converted to prednisone equivalents (25mg cortisone = 20mg 
hydrocortisone= 4mg methylprednisolone= 5mg prednisone= 5mg prednisolone 
= 4mg triamcinolone= 0.75mg betamethasone = 0.75mg dexamethasone). 19-22 
Analysis 
We used the self-controlled case series method to examine whether the risk of 
Ml was greater while an individual took a GC or shortly thereafter compared to 
times when they were not taking GCs. Specifically, we examined the period 
while each subject was taking the GC, and the 42-day period after the subject 
stopped taking the GC. The 6 weeks after drug exposure was divided into four 
blocks: 2 one week blocks directly after drug exposure finished; and 2 two week 
blocks after this (Figure 2.1). 
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Figure 2.1: Classification of follow-up time in a typical Ml case 
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Event-dependent exposure can create bias in sees studies (see the General 
lntroduction).23 To account for this we defined a 4 week 'risk' period prior to Ge 
exposure (Figure 2.1 ). This removes from the baseline risk period Ml cases that 
could have occurred at an artificially high rate because Ge exposure sometimes 
results from the hospitalization. (This apparently elevated case rate is an artifact 
of the sees method; exposure sometimes occurs in the period after 
hospitalization because the hospitalization itself leads to Ge prescribing , 
presumably during and then after the hospitalization.) The 'risk ratio' during this 
period does not represent a 'causal' relation, and should not be interpreted as 
such. Also note that 'adjusting' for outcome-dependent exposure does not 
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control for time-dependent confounding by indication; i.e. an illness for which 
GCs may be prescribed and which independently 'causes' Ml can still confound 
an apparent GC-MI relationship (see below). 
We used SAS v. 9.1 (SAS Institute, Inc., Cary, NC) for all SCCS analyses. 
Poisson regression was used to calculate relative incidences (Ris) . We used 5 
year bands of age (aside from the first which encompassed ages 18-25) to 
control for age effects. 
Confounding by indication 
The self-controlled case series method eliminates time-invariant confounding , but 
does not necessarily limit confounding factors that vary over time. Since 
confounders within individuals are less likely to vary within short periods 
compared to confounders between individuals, the method is very appealing for 
use in pharmacoepidemiologic studies. However we recognize that when 
persons are followed for significant periods of time, for example several years as 
in this study, confounding, especially confounding by indication , can be a 
significant factor. 
Though GCs are not generally prescribed for cardiovascular conditions and we 
therefore feel there is unlikely to be confounding by indication for this reason in 
our study, it is true that GCs may be prescribed for conditions that coexist with 
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MI. An example would be COPD. COPD and cardiovascular disease (CVD) 
have a number of risk factors in common, especially smoking. COPD flares are 
commonly treated with GCs. Therefore a putative association between GCs and 
Mls could reflect the fact that persons with COPD are likely to be treated with 
GCs and likely to develop CVD including MI. There may be other diseases 
treated with GCs that are also associated with a higher incidence of MI. 
Therefore any analysis of a GC-MI relationship will need to account for this 
potential source of confounding . We attempted to take advantage of the fact 
that, unlike COPD, not all diseases treated with GCs are associated with MI. An 
example would be a rash . Though common , most rashes are not thought to 
increase the risk of CVD. Therefore any GC-MI association in a subset of 
persons with a rash is more likely to reflect a true causal relationship . 
We attempted to identify the reason for which each individual burst GC 
prescription in this cohort was issued and to repeat our main analysis in different 
disease subsets to see whether the GC-MI relationship remained stable. 
Identifying indications for GC prescriptions 
In the entire burst cohort we identified the date that each prescription was most 
likely dispensed to each patient and assumed that each patient would begin 
using the GC on that date. PBM records include both dates that prescriptions 
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are ordered and dispensed. We used the dispensation date when recorded and 
the date the prescription was ordered when the dispensation date was missing. 
We examined all outpatient visits in the one week before this date (including the 
date itself) and identified visits to clinics and clinic personnel who were likely to 
prescribe GCs (i.e. physicians, physician assistants, and nurse practitioners, but 
excluding mental health services providers) . We then identified the ICD-9 codes 
associated with each of these visits. 
We created three groups of codes (see Table 2.1, 'Group' column): the first 
group included codes for diseases that we felt could reasonably result in a GC 
prescription (group 1: e.g. COPD, asthma, gout, rheumatoid arthritis). Another 
group represented codes for those diseases unlikely to result in a GC 
prescription (group 3: e.g. most infectious and cardiovascular diseases, and 
mental health diagnoses). A third group represented those conditions that did 
not fall into either of the two previous groups; i.e. diseases that are not usually 
treated with GCs but in which it is conceivable that they could be used (group 2: 
e.g. sinusitis, low back pain, bronchitis). 
We then looked for group 1 conditions occurring in the week before the 
prescription. The group 1 condition occurring on the visit closest to the date of 
the prescription (and highest on the list of diagnoses for each visit) was 
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presumed to be the indication for the prescription. If no group 1 code existed in 
the prior week, we looked for group 2 codes; if no group 2 codes existed either, 
we looked for group 3 codes. In any case, the code closest to the issue date and 
highest on the code list was chosen . If no acceptable code was found then the 
indication for the prescription was left blank. 
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Table 2.1: Classification of indications for GC prescriptions 
Category Subcategory I.CD-9 Codes Group 
Respiratory 
COPD 491JCK. 492J<X. 496J<X 1 
asthma 493J<X 1 
acute bronchitis. upper 465J<X. 466J<X. 490J<X. 2 
respiratory infection 
pneumoconioses 50XJ<X 3 
other respiratory symptoms 786J<X (but not 786.5X. chest 2 
(dyspnefl, cough, stridor, pain} 
hemoptysis, etc.) 
other respiratory conditions 47XJ<X, 49XJCK (except as 3 
above), 5l XJCK 
Infection 
sinusitis 461 J<X, 473J<X 3 
pneumonia 48XJ<X. 3 
other infections OXX.XX. 10X.XX, 11X.XX, 3 
12x.XX, 13XJCK 
Skin conditions 
'inflammatory' skin 69X.XX 1 
conditions 
other skin conditions 68X.XX, 70X.XX, 782.XX 2 
Autoimmune 
disease& 
'inflammatory' joint and Gl 71 OJ<X, 712J<X~ 713JCK, 1 
diseases 7l4JCK, 720J<X, 725J<X, 
vasculitis 446J<X 1 
multiple sclerosis 340.X, 341.XX 1 
JOint and 
mu&eula&keletal 
conditions 
gout 274.XX 1 
CPPD disease 712.XX 1 
spine diseases 721.XX, 722JCK. 723.XX, 724.XX 2 
'rheumatism' 726.XX, 727 .XX. 728.XX, 729.XX 2 
other musculoskeletal 71X.XX (except as above). 3 
73X.XX 
Other 
malignancy 14X.XX, 1SX.XX, 16X.XX, 2 
17XJCK, 18X.XX. 19X.XX, 
20X.XX, 21X.XX, 22}(_)0{, 
23X.XX 
other neurologic asx.xx 2 
allergic 995.XX 2 
all others 
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Analyses stratified by indication 
We repeated our main analysis in persons with various diagnoses. If 
confounding by indication was present we expected to see differences in the size 
of the effect measures and would expect to see null GC-MI relationships in some 
groups. 
Because of the large number of possible GC indications we grouped them in two 
ways (Table 2.1 ). First, we used broad categories of disease: respiratory 
diseases, infectious diseases, skin diseases, joint/limb/spine disease, 
cardiovascular diseases, systemic diseases, and other indications. Next we 
used more specific categories that reflected groups of diseases for which GCs 
are prescribed as well as other diagnoses for which they might not be prescribed. 
These were: COPD, asthma, cough/dyspnea/wheezing, other respiratory 
diseases, pneumonia, bronchitis and upper respiratory tract infections, sinusitis, 
pneumoconioses, other infections, inflammatory skin diseases, other skin 
diseases, gout, calcium pyrophosphate dihydrate (CPPD) disease, back and 
neck conditions, peripheral joint/limb conditions, ischemic heart disease, 
congestive heart disease, chest pain, diabetes, hypertension/hyperlipidemia, 
'allergy', cancer, inflammatory joint and Gl diseases, vasculitides, multiple 
sclerosis and related diseases, Bell's palsy, other neurologic diseases, and other 
disease (any that did not fall into any of the previous categories). 
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Another analysis grouped indications by those that we felt were likely or unlikely 
to confound the GC-MI relationship. Indications we felt could reasonably be 
expected to act as confounders included COPD, chest pain, inflammatory joint 
and Gl diseases, and vasculitis; all these are known or felt to carry an 
independent risk of cardiovascular disease. Indications that we felt were unlikely 
to confound the relationship included asthma, bronchitis and upper respiratory 
infections, sinusitis, back/neck conditions, Bell's palsy, CPPD, and multiple 
sclerosis; these are not known or expected to be risk factors for cardiovascular 
diseases. 
Some of these groups were very small and the results of analyses in these small 
groups are not presented. Results from others are given with the same risk 
windows as in the main analysis. All these analyses were performed only in 
those persons with a single GC prescription over their follow-up time. 
Other sensitivity analyses 
We performed a number of additional analyses: First, we limited follow-up time 
to the 2 years before and after GC exposure to limit the effect of comorbidities 
that might vary over time. Second, we performed an analysis using a broader 
case definition. This included codes for both 'acute' and 'past' Mls (41 O.XX and 
412.XX) as well as those for postmyocardial infarction syndrome (411 .XX) and 
cardiac arrest (427.5). 
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Finally, we repeated our main analysis in a cohort of patients who had used 
ciprofloxacin rather than glucocorticoids. Ciprofloxacin is used similarly to GCs in 
that they are often used infrequently and in short courses. Our rationale was that 
there is no known effect of this antibiotic on the occurrence of heart disease and 
none is theorized to be present; therefore, if a 'causal' effect is apparent it might 
indicate that confounding by indication is present. In this case, confounding 
would probably occur because persons who use antibiotics are more likely to be 
ill in general, and therefore more likely to suffer MI. This could also be the case 
with GCs. If the effect was similar, it could indicate that any observed 
relationship between GCs and Ml was indeed the effect of unmeasured 
confounding. We formed our ciprofloxacin cohort using exactly the same 
definitions as in our GC cohort; however, because the ciprofloxacin cohort was 
much larger than the GC cohort, our computer resources were insufficient to run 
this analysis on the full cohort and we therefore limited the follow-up period to 
FY2005-FY2008. 
RESULTS 
The initial cohort of burst GC users comprised 627,306 subjects whose use of 
GCs met our definition of GC bursts. (Further details pertaining to the burst 
cohort are given in the appendix, as are VA 'priority' definitions.) Of these, 6371 
had an MI. After excluding those with relevant hospitalizations and those whose 
events fell outside of their enrollment period (4409), we were left with an analysis 
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cohort of 1962 persons (Figure 2.2). Of these, 97.5% were men, mean age (sd) 
was 65.4 (1 0.2) (66.5 years (11.3) for men, 58.5 (13. 7) for women). 76.5% were 
white, 10.2% African American, 5.0% black or white Hispanic, and 8.3% other 
(Table 2.2) 
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Figure 2.2: Subject flow 
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Table 2.2: Ml case characteristics 
All Men Women 
N (%) 1962 (100) 1913 (97.5) 49 (2.5) 
Mean age at Ml (std) 66.5 (11.3) 65.4 (10.2) 58.5 (13.7) 
Race- N (%) 
White 1500 (76.5) 1471 (76.9) 20 (59.2) 
Black 200 (1 0.2) 190 (9.9) 10 (20.4) 
Hispanic/AA 5 (0.3) 5 (0.3) 0 
Hispanic/white 93 (4.7) 91 (4.8) 2 (4.1) 
American Indian 10 (0.5) 10 (0.5) 0 
Asian 7 (0.4) 6 (0.3) 1 (2.0) 
Pacific Islander 12 (0.6) 12 (0.6) 0 
Unknown 135 (6.9) 128 (6.7) 7 (5.2) 
Priority - N (%) 
1 253 (12.9) 243 (12.7) 10(20.4) 
2 98 (5.0) 93 (4.9) 5 (1 0.2) 
3 212 (10.8) 207 (1 0.8) 5 (1 0.2) 
4 29 (1.5) 29 (1 .5) 0 
5 1145 (58.4) 1125 (58.8) 20 (1 0.8) 
6 17 (0.9) 17 (0.9) 0 
7 26 (1.3) 24 (1.3) 2 (4.1) 
8 182 (9.3) 175 (9.2) 7 (14.3) 
N of GC bursts 
median (Q1, Q3) 1 (1' 2) 1 (1' 1) 1 (1' 2) 
mean (sd) 1.4 (0.8) 1.4 (0.8) 1.4 (0.6) 
In the 1962 subjects, there were 2695 GC prescriptions (Table 2.3). Most 
subjects (75%) received only 1 prescription over the time they were followed, and 
roughly two thirds of prescriptions were for 7 days or less. Prednisone was the 
most frequently prescribed GC (62.2% or prescriptions) and methylprednisolone 
constituted most of the rest (33.5%). 
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Table 2.3: GC prescription characteristics 
All Men Women 
Total number of burst GC 2695 2628 67 
prescriptions 
No. of GC prescriptions 
per person- N (%) 
1 1471 (75.0) 1438 (75.2) 33 (67.4) 
2 347 (17.7) 332 (17.4) 15 (30.6) 
3 94 (4.8) 94 (4.9) 0 
4 27 (1.4) 26 (1.4) 1 (2.0) 
5 14(0.7) 14 (0.7) 0 
6 4 (0.2) 4 (0.2) 0 
7 2 (0.1) 2 (0.1) 0 
8 1 (0.1) 1 (0.1) 0 
10 1 (0.1) 1 (0.1) 0 
14 1 (0.1) 1 (0.1) 0 
Length of GC burst 
1-7 days 1754 (65.08) 1707 (64.95) 47 (70.15) 
> 7 days 941 (34.92) 921 (35.05) 20 (29.85) 
GCs prescribed - N (%) 
prednisone 1676 (62.2) 1637 (62.3) 39 (58.2) 
methylprednisolone 902 (33.5) 877 (33.4) 25 (37 .3) 
dexamethasone 110(4.1) 107 (4.1) 3 (4.5) 
hydrocortisone 4 (0.2) 4 (0.2) 0 
prednisolone 2 (0.1) 2 (0.1) 0 
cortisone 1 (0.0) 1 (0.0) 0 
The median length of GC prescription was 6 days (IQR 6, 1 0). The median and 
mean daily dose of each GC burst was 17.5mg (IQR 17.5, 23.3) and 22.4mg (SO 
21.6) respectively (Tables 2.4 and 2.5). 
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Table 2.4: Mean and median lengths (days) of GC prescriptions 
Glucocorticoid All Men Women 
median (Q1 , Q3) 
mean (sd) 
all 6 (6, 10) 6 (6, 10) 6 (6, 10) 
8.8 (6.6) 8.8 (6.6) 7.6 (5.3) 
prednisone 8(4, 12) 8 (5, 12) 5 (7, 12) 
9.9 (7.1) 9.9 (7.2) 8.4 (5.5) 
methylprednisolone 6 (6, 6) 6 (6, 6) 6 (6, 6) 
6.3 (3.0) 6.3 (3.0) 6.8 (4.9) 
dexamethasone 7 (3, 20) 7(3,21) 1 (1 ' 7) 
11.6 (11 .0) 11 .9 (11.0) 3.0 (3.5) 
hydrocortisone 17.5 (4, 30) 17.5 (4, 30) 
17.0 (15.0) 17.0 (15.0) 
prednisolone 17(4, 30) 17.0 (4.0, 30.0) 
17(18.4) 17.0 (18.4) 
cortisone 5 (5, 5) 5 (5, 5) 
5 (-) 5 (-) 
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Table 2.5: Mean and median dose (mg) of GC prescriptions 
Glucocorticoid All Men Women 
median (Q1, Q3) 
mean (sd) 
all 17.5 (17.5, 23.3) 17.5 (17.5, 23.3) 17.5 (17.5, 20.0) 
22.4 (21.6) 22.5 (21.7) 21.2 (16.0) 
prednisone 20 (16.3, 25.0) 20.0 (16.3, 25.0) 20.0 (15.7, 25.0) 
24.2 (23.1) 24.2 (23.1) 23.8 (19.9) 
methylprednisolone 17.5 (17.5, 17.5) . 17.5 (17.5, 17.5) 17.5 (17.5, 17.5) 
18.0 (1 0.3) 18.0 (10.4) 17.2 (6.2) 
dexamethasone 26.7 (6.7, 26.7) 26.7 (6.7, 26.7) 26.7 (26.7, 26.7) 
33.8 (45.9) 34.2 (46.5) 20.3 (11.0) 
hydrocortisone 2.5 (2.5, 3.8)) 2.5 (2.5, 3.8) 
3.1 (1.3) 3.2 (1.3) 
prednisolone 11.6 (7.5, 15.7) 11.6 (7 .5, 15.7) 
11.6 (5.8) 11.6 (5.8) 
cortisone 5 (5, 5) 5 (5, 5) 
5 (-) 5 (-) 
We were unable to determine the cause for more than a quarter (27.8%) of GC 
prescriptions using our algorithm (Table 2.6). Another quarter (29.0%) appeared 
to be prescribed for respiratory reasons, and another quarter (20.2%) for 
conditions of the joint, spine, or limb. The most common conditions for which 
GCs were prescribed were COPD (13.9%), spine disorders (6.7%), peripheral 
joint/limb disorders (8.5%), and skin diseases (1 0.8%). 
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Table 2.6: Indications for burst GC prescriptions 
Indications Number % 
No. of burst GC prescriptions 2695 100 
Unable to identify indication 750 27.83 
Respiratory 782 29.02 
COPD 374 13.88 
bronchitis/URI 183 6.79 
asthma 101 3.75 
other respiratory 48 1.78 
cough/DOE/wheeze 73 2.71 
pneumoconioses 3 0.11 
Joint/Spine/Limb 545 20.22 
back/neck 180 6.68 
peripheral 228 8.46 
gout 137 5.08 
Skin 291 10.80 
inflammatory skin 147 5.45 
other skin 144 5.34 
Other 189 7.01 
cancer 86 3.19 
"allergy" 62 2.30 
other neurologic 41 1.52 
Infection 108 4.01 
sinusitis 41 1.52 
other infection 38 1.41 
pneumonia 29 1.1 
Systemic 30 1.11 
inflammatory joinUGI 26 0.96 
MS and related 1 0.03 
vasculitis 3 0.11 
Results from the sees analysis suggested that persons taking a Ge had an 
elevated risk of Ml compared to the baseline period (RI = 4.5, 95% e1 3.1-6.7) 
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(Table 2.7) . The elevated 'risk' of Ml in the period before exposure indicates that 
there is event-dependent exposure, i.e. the rate of Ml appears elevated because 
hospitalization for Ml is a risk for GC prescription. This 'risk' measure should not 
be interpreted causally. 
Table 2. 7: Main results of the sees analysis 
Number of Ml cases 
in risk period 
N 1962 
baseline 1721 
28-1 days prior to prescription 125 
days 0-6 on GC 26 
days 7-28 on GC 10 
1-7 days after discontinuation 16 
8-14 days after discontinuation 12 
15-28 days after discontinuation 32 
29-42 days after discontinuation 20 
Effects of Ge indication 
Relative 
incidence 
1 (ref) 
4.0 
4.5 
3.5 
2.3 
1.7 
2.1 
1.3 
95%CI 
3.3, 4.8 
3.0, 6.6 
1.8, 6.5 
1.4, 3.7 
1.0, 3.0 
1.5, 2.9 
0.8, 2.0 
On repeat analysis in each presumed GC indication, our results were broadly 
similar to those given in the main analysis (Tables 2.8 to 2.16). A comparable 
elevation in the risk of Ml during GC exposure followed by a decline once GCs 
were discontinued was observed in most cases . Many of these analyses were 
limited by small numbers. The tables presented show a sample of these 
analyses. 
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Table 2.8: sees analysis in those prescribed Ges for respiratory 
conditions 
Number of Ml cases Relative 95%CI 
in risk period incidence 
N 339 
baseline 304 1 (ref) 
28-1 days prior to prescription 9 2.1 1.1, 4.0 
days 0-6 on GC 5 6.1 2.5, 14.8 
days 7-28 on GC 2 7.1 1.7, 29.4 
1-7 days after discontinuation 4 4.1 1.5,11.0 
8-14 days after discontinuation 2 2.0 0.5, 8.1 
15-28 days after discontinuation 8 3.7 1.8, 7.5 
29-42 days after discontinuation 5 2.3 0.9, 5.5 
Table 2.9: sees analysis in those prescribed Ges for non-respiratory 
conditions 
Number of Ml cases Relative 95%CI 
in risk period incidence 
N 712 
baseline 653 1 (ref) 
28-1 days prior to prescription 32 3.6 2.5, 5.1 
days 0-6 on GC 8 4.7 2.3, 9.4 
days 7-28 on GC 1 1.2 0.2, 8.3 
1-7 days after discontinuation 2 1.0 0.2, 4.0 
8-14 days after discontinuation 2 1.0 0.2, 4.0 
15-28 days after discontinuation 8 1.8 0.9, 3.6 
29-42 days after discontinuation 6 1.3 0.6, 3.0 
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Table 2.10: sees analysis in those prescribed Ges for eOPD 
Number of Ml cases Relative 95%CI 
in risk period incidence 
N 157 
baseline 139 1 (ref) 
28-1 days prior to prescription 5 2.3 0.9, 5.6 
. days 0-6 on GC 2 4.9 1.2, 19.9 
days 7-28 on GC 2 13.0 3.1, 55.7 
1-7 days after discontinuation 3 6.1 1.9,19.4 
8-14 days after discontinuation 0 
15-28 days after discontinuation 4 3.7 1.4,10.1 
29-42 days after discontinuation 2 1.8 0.4, 7.4 
Table 2.11: sees analysis in those prescribed Ges for skin conditions 
Number of Ml cases Relative 95%CI 
in risk period incidence 
N 201 
baseline 172 1 (ref) 
28-1 days prior to prescription 18 8.3 5.1, 13.7 
days 0-6 on GC 4 9.6 3.6, 26.1 
days 7-28 on GC 0 
1-7 days after discontinuation 1 2.0 0.3, 14.7 
8-14 days after discontinuation 1 2.0 0.3, 14.5 
15-28 days after discontinuation 2 1.8 0.5, 7.5 
29-42 days after discontinuation 3 2.7 0.9, 8.6 
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Table 2.12: sees analysis in those prescribed Ges for non-skin conditions 
Number of Ml cases Relative 95%CI 
in risk period incidence 
N 850 
baseline 785 1 (ref) 
28-1 days prior to prescription 23 1.4 1.4, 3.1 
days 0-6 on GC 9 4.3 2.2, 8.2 
days 7-28 on GC 3 3.1 1.0, 9.6 
1-7 days after discontinuation 5 2.0 0.8, 4.8 
8-14 days after discontinuation 3 1.2 0.4, 3.7 
15-28 days after discontinuation 14 2.5 1.5, 4.3 
29-42 days after discontinuation 8 1.4 0.7, 2.9 
Table 2.13: sees analysis in those prescribed Ges for joint/limb/spine 
conditions 
Number of Ml cases Relative 95%CI 
in risk period incidence 
N 305 
baseline 294 1 (ref) 
28-1 days prior to prescription 2 0.5 0.1, 2.0 
days 0-6 on GC 3 3.9 1.2,12.2 
days 7-28 on GC 0 
1-7 days after discontinuation 0 
8-14 days after discontinuation 1 1.1 0.2, 7.9 
15-28 days after discontinuation 3 1.5 0.5, 4.7 
29-42 days after discontinuation 2 1.0 0.2, 4.0 
68 
Table 2.14: sees analysis in those prescribed Ges for non-joint/limb/spine 
conditions 
Number of Ml cases Relative 95%CI 
in risk period incidence 
N 746 
baseline 663 1 (ref) 
28-1 days prior to prescription 39 4.2 3.0, 5.8 
days 0-6 on GC 10 5.7 3.0, 10.7 
days 7-28 on GC 3 3.6 1.1 , 11.3 
1-7 days after discontinuation 6 2.9 1.3, 6.4 
8-14 days after discontinuation 3 1.4 0.5,4.4 
15-28 days after discontinuation 13 2.8 1.6, 4.9 
29-42 days after discontinuation 9 1.9 1.0, 3.7 
Table 2.15: sees analysis in those prescribed Ges for 'associated' 
conditions (eOPD, chest pain, inflammatory joint/GI, vasculitis) 
Number of Ml cases Relative 95%CI 
in risk period incidence 
N 316 
baseline 282 1 (ref) 
28-1 days prior to prescription 9 1.8 0.9, 3.5 
days 0-6 on GC 6 6.2 2.7, 13.9 
days 7-28 on GC 4 7.8 2.8, 21.4 
1-7 days after discontinuation 3 2.7 0.9, 8.3 
8-14 days after discontinuation 1 0.9 0.1, 6.3 
15-28 days after discontinuation 4 1.6 0.6, 4.4 
29-42 days after discontinuation 7 2.8 1.3, 5.9 
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Table 2.16: sees analysis in those prescribed Ges for 'non-associated' 
conditions (asthma, bronchitis/URI, sinusitis, back/neck conditions, Bell 
palsy, ePPD, MS) 
Number of Ml cases Relative 95%CI 
in risk period incidence 
N 421 
baseline 402 1 (ref) 
28-1 days prior to prescription 1 0.2 0.0, 1.2 
days 0-6 on GC 4 3.4 1.3, 9.1 
days 7-28 on GC 0 
1-7 days after discontinuation 1 0.7 0.1' 5.1 
8-14 days after discontinuation 2 1.5 0.4, 5.7 
15-28 days after discontinuation 9 2.9 1.5, 5.7 
29-42 days after discontinuation 2 0.6 0.2, 2.6 
Table 2.17: Summary of results stratified across various disease 
indications 
Condition Rl with condition Rl without condition 
(N for each column) (1st 6 day period) (1st 6 day period) 
Respiratory Diseases 6.2 4.7 (339, 712) 
Joint Diseases 3.9 5.7 (305, 746) 
Skin Diseases 9.5 4.3 (201 ' 850) 
COPD (157) 5.1 
'Associated' conditions 6.2 (316) 
'Unassociated' 3.4 
conditions (421) 
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Other sensitivity analyses 
Broader Ml definition 
There was essentially no change in risk using the broader Ml definition given 
above (Table 2.18) or when limiting exposure to the 2 year years around GC 
exposure (Table 2.19). 
Table 2.18: sees results using the broader definition of Ml 
Number of Ml cases Relative 95%CI 
in risk period incidence 
N 2090 
baseline 1838 1 (ref) 
28-1 days prior to prescription 131 3.9 3.3, 4.7 
days 0-6 on GC 26 4.2 2.9, 6.2 
days 7-28 on GC 10 3.3 1.7, 6.2 
1-7 days after discontinuation 17 2.3 1.4, 2.6 
8-14 days after discontinuation 13 1.7 1.0, 3.0 
15-28 days after discontinuation 33 2.0 1.4, 2.8 
29-42 days after discontinuation 22 1.3 0.9, 2.0 
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Table 2.19: sees results where follow-up was limited to the 2 years around 
exposure 
Number of Ml cases Relative 95%CI 
in risk period incidence 
N 1517 
baseline 1276 1 (ref) 
28-1 days prior to prescription 125 3.5 2.9, 4.2 
days 0-6 on GC 26 4.0 2.7, 5.9 
days 7-28 on GC 10 3.0 1.6, 5.6 
1-7 days after discontinuation 16 2.0 1.2, 3.3 
8-14 days after discontinuation 12 1.5 0.9, 2.7 
15-28 days after discontinuation 32 1.9 1.3, 2.6 
29-42 days after discontinuation 20 1.2 0.7, 1.8 
Ciprofloxacin comparison 
When we re-ran our analysis using 'burst' ciprofloxacin use as the exposure 
rather than GCs, the results were remarkably similar to those in the main 
analysis (Table 2.20) . Note that in the 'pre-exposure' period the risk ratio is 
elevated compared to the GC analysis, indicating that there is a higher rate of 
ciprofloxacin prescription after hospitalization for Ml than GC prescriptions. It is 
probably to be expected that there would be more antibiotics prescribed after a 
hospitalization than GCs. 
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Table 2.20: sees results in the ciprofloxacin cohort 
Number of Ml cases Relative 95%CI 
in risk period incidence 
N 4136 
baseline 3278 1 (ref) 
28-1 day_s prior to prescription 429 5.2 4.7, 5.7 
days 0-6 on GC 82 4.6 3.7, 5.7 
days 7-28 on GC 29 3.4 2.3, 4.9 
1-7 days after discontinuation 65 3.1 2.4, 3.9 
8-14 days after discontinuation 44 2.1 1.5, 2.8 
15-28 days after discontinuation 58 1.3 1.0, 1.6 
29-42 days after discontinuation 88 1.9 1.5, 2.3 
DISCUSSION 
Interpretation 
Our results show an elevated risk of Ml while subjects are using GCs with a 
decline in risk over the subsequent 6 weeks compared to other periods when 
they are not. There are two possible interpretations for this result: 1) GC use is 
causally associated with an elevated risk of Ml and this risk declines as the drug 
'washes out'; 2) the increase in 'risk' represents confounding by indication by 
other medications, diseases, or general conditions of health. 
Our sensitivity analyses were helpful in sorting out which of the above options is 
true. First note that even after stratifying by several different diseases, some of 
which might independently be associated with Ml (e.g. , COPD), and some of 
which should not be (e.g., skin conditions), there is a persistent association 
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between GC use and Ml, and that the risk is often higher in persons with the 
condition than in those without. This would suggest that GC use does indeed 
increase the risk of Ml but that confounding by indication is also present: there is 
an apparent residual risk of Ml no matter how the data are analyzed which we 
should see fall to null if the association is only due to confounding by indication. 
Then, in the ciprofloxacin cohort, we see a very similar pattern with ciprofloxacin 
use and an elevated risk of Ml as in the primary analysis. However, based on 
the lack of any data that suggests a relationship between ciprofloxacin use and 
Ml, and any physiological mechanism whereby this might occur, we expected this 
relationship to be null. The fact that it is not suggests that confounding is present 
in this analysis, and this in turn , since the effect sizes are quite similar, suggests 
that uncontrolled confounding may be present in the GC cohort as well. We 
could not further isolate the source of this confounding, but theoretically it should 
be time-dependent changes occurring within each subject, including acute 
illnesses, new chronic illnesses, drug use, and , perhaps, general health. 
Results in context 
At least three population-based studies have suggested that there is an elevated 
risk of Ml in those using GCs. Varas-Lorenzo and colleagues found an elevated 
risk of acute Ml in GC users compared to GC non-users in the General 
Practitioners Research Database (GPRD).10 The risk was higher in persons 
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'currently' using GCs, and in those using higher doses of GCs. Wei and 
colleagues found a similar elevated risk for cardiovascular disease among GC 
users in Tayside Scotland using a similar database (the Medicines Monitoring 
(MEMO) unit), and Souverein and colleagues found a relationship between GC 
use and cardiovascular and cerebrovascular events, again using GPRD.11 •12 
Similar relationships have been suggested in disease-specific patient cohorts as 
well , including subjects with COPD, RA, and SLE. 14·24-28 
There are also non-epidemiologic and animal data supporting the hypothesis that 
GC use leads to cardiovascular disease. These include studies showing 
elevated blood pressure and lipids which are known risk factors for CVD, 
depressed insulin sensitivity among GC users, and detrimental effects of GCs on 
intimal medial thickness (IMT), carotid plaques, and arterial incompressibility in 
RA and SLE patients. 2-9·29-33 
However, these data are by no means conclusive. Other epidemiologic studies, 
including in those with polymyalgia rheumatica and RA, show no relationship 
between GC use and cardiovascular disease, and other studies suggest that GC 
use may have a small protective effect, or at least a null effect, in either all RA 
patients or seronegative RA patients.24·34-36 Further, it has been hypothesized 
that the risk of Ml is associated with the extent of chronic inflammation, and that 
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controlling that inflammation, including through the use of Ges, may be 
desirable.35·37 
There is also good reason to suspect that many studies have inadequately 
controlled for confounding. For instance, the three above general population 
studies included all Ge users. 10-12 But Ge users are more likely to suffer from 
some chronic diseases, including RA and SLE, that have now convincingly been 
shown to be associated with an elevated risk of Ml and other cardiovascular 
events.38•39 It is not clear that these population-based studies adequately 
adjusted for the presence of these diseases in their cohorts; indeed it would be 
very difficult to do so. The disease-specific cohorts also could suffer from 
inadequately differentiating disease severity, as opposed to Ge use, as the 
cause for cardiovascular disease. 
For these reasons, we attempted this sees analysis. We reasoned that a 
within-person design would help to minimize the effects of having a chronic 
inflammatory disease and disease severity in those with these diseases. We 
also reasoned that showing an acute risk of Ml while persons were using Ge 
would add additional support to the hypothesis that Ges, when used chronically, 
could cause MI. 
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However, our results suggest that uncontrolled confounding, despite the within-
person study design, could be present in our study. This suggests that 
uncontrolled confounding could also be present in other studies and weighs 
against those studies showing a Ge-M I link. However, we also acknowledge that 
the acute effects of Ges that we studied here may not be comparable to the 
chronic effects studied in all other studies. 
Limitations 
Users of VA services can still receive medications and services outside of the 
VA. In this study, if a person received Ges outside of VA or had an Ml outside 
VA, these would not have been captured in our data. This should not have 
biased our results since this a case study method and both Ge use and Ml were 
requirements to enter our study, unless subjects received Ges·from both sources 
and/or had more than one Ml of which only one of which was captured here. We 
tried to ensure that subjects in our study were at least receiving care in the VA on 
a regular basis by requiring at least one visit in each consecutive calendar year, 
making it more likely that they are regular VA users. 
A potential source of confounding can occur in sees studies if the event affects 
future prescribing of the exposure of interest. We took this into account, in part, 
by studying only first Mls. 
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We note that our definition of acute Ml , based on administrative data, has been 
used and validated in a number of prior studies including in VA databases. 12-18 
Conclusion 
Based on the above considerations, we think it unlikely that burst GC use is 
associated with Ml, or at least that GC use acts as a trigger for MI. We believe 
that the apparent association is likely to be driven by uncontrolled confounding, 
either by indication or by general health . Though this study does not directly 
contradict the results of other studies, as other studies were concerned with 
chronic rather than burst GC use, it does suggest that confounding may play a 
role in those studies. This is further supported by the small number of studies 
that did not find a relationship between GC use and Ml ; it is possible that these 
studies more adequately adjusted for confounding effects.24•34-36 
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THE SHORT TERM RISK OF UPPER GASTROINTESTINAL BLEEDING 
ASSOCIATED WITH BURST GLUCOCORTICOID USE IN US VETERANS 
INTRODUCTION 
Glucocorticoids (GCs) are commonly used medications that mimic the use of 
endogenous corticosteroids. They are highly effective anti-inflammatory agents 
that have revolutionized many aspects of medical practice; indeed their discovery 
lead to the Nobel Prize for their discoverers, Kendall , Reichstein, and Hench, in 
1950.1 Unfortunately a host of serious and common side effects accompany 
their use and can lead to major medical complications. 
It has been reasonably well established that upper gastrointestinal bleeding (GIS) 
is one of these complications.2-6 The establishment of GC use as a risk factor for 
GIS was by no means easy; persons who initially received these medications 
were often quite ill and likely had additional risk factors for GIS besides 
medications.4 The later development of effective non-steroidal anti-inflammatory 
drugs (NSAIDs) further muddied the waters, as these medications were 
frequently given to similar populations as those using GCs and eventually came 
to be clearly associated with a marked elevation in risk of GIS that overshadowed 
that due to GCs.7·8 Today, despite good evidence of an elevated , though small, 
GIS risk with GC use (about 1.5- to 2-fold) , this association has been 
overwhelmed in the minds of many by the greater risk associated with NSAIDs or 
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else entirely ignored. 9 Either that or, because of the numerous other side effects 
of GC use, practitioners may be unaware of the GIB risk associated with GC use. 
Whatever the awareness of the risk among practitioners, what is clear is that 
prior studies establishing a GIB risk were almost exclusively done in populations 
using GCs chronically. 4·6·10-12 However, we know that GCs act relatively rapidly, 
and clearly can have fairly rapid physiologic effects but we have no idea whether 
these rapid physiologic effects lead to a concurrent risk of Gl bleeding.13-20 We 
designed this self-controlled case series (SCCS) study to address this issue, i.e. 
whether short 'bursts' of GC use can act as a 'trigger' for GIB while or shortly 
after their use. The design has the additional advantage of eliminating between-
person confounding, minimizing the effects of other diseases or chronic 
medication use. 
METHODS 
Study design 
This was a self-controlled case series study as described in the General 
Introduction. This design eliminates between-person confounding and time-
invariant confounding within individuals. It is especially suitable for studies of 
'triggers' of acute events as here, where short-term use of GCs may act as a 
trigger for GIB. 
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GC burst cohort 
The underlying cohort is those veterans who had received only burst GCs within 
the US Veterans Affairs 0/A) healthcare system, defined as follows : We first 
took those persons who had ever received , as an outpatient, either an oral or an 
IV prescription of any of the following GCs: betamethasone, budesonide, 
cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisone, 
prednisolone, and triamcinolone. We limited this group to those persons who 
had received only burst prescriptions. We defined a burst prescription as one of 
30 days or less, and for which there was at least 6 weeks (42 days) before and 
after free of any other GC prescription. 
Individual subjects could exit and re-enter the burst cohort. For example, if a 
subject entered the VA and was followed for some years, was lost to follow-up 
(defined as less than 1 visit in 2 consecutive calendar years) , and then re-
entered the VA for another period of years, both periods could be included in the 
follow-up time if the person otherwise met the criteria for burst use. 
Case ascertainment 
Within the burst cohort, we identified those persons who had been hospitalized 
for a first GIB. We defined hospitalization for GIB as an ICD-9 code located in 
the primary or secondary position of the discharge summary associated with an 
admission . Codes included 531 .xx (gastric ulcer with hemorrhage/perforation) or 
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532.xx (duodenal ulcer with hemorrhage/perforation). This case definition has 
been validated and used in other database studies, including VA studies. 14·21 -25 
For this analysis the burst cohort was limited to those who met this definition. 
Further inclusion criteria 
To limit exposure misclassification, after finding those subjects in the burst cohort 
who met the GIB definition, we excluded persons who could have received a GC 
during a previous hospitalization. From FY2004 through FY2008 VA Pharmacy 
Benefits Management (PBM) data contains a complete record of inpatient drug 
administration. Therefore we identified whether each individual had ever 
received a GC while an inpatient, and if they had done so within 6 months of the 
GIB admission, they were excluded from the analysis cohort for this study. 
For FY1999 through FY2003 inpatient drug administration records are not 
complete; therefore during this time period if a subject had been hospitalized 
within the 6 months prior to the GIB admission they were excluded from the 
analysis cohort since we could not tell whether they might have received a GC 
(which are often prescribed to inpatients). 
To further limit exposure misclassification, we excluded persons whose first burst 
GC prescription occurred during the first year of their follow-up as they could 
have received another GC from another source prior to their VA enrollment. 
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Similarly, we excluded persons who had their 'first' GIB within their fi rst year of 
follow-up as this could have represented a recurrence that was not documented 
in VA records. 
Because NSAID and GC prescriptions can have similar indications, and because 
NSAID use is a well-known risk factor for GIB, we excluded the small number of 
persons (eight) who had used NSAIDs over the follow-up period. 
Exposure definitions 
GC bursts are often given as a 'burst and taper' with the initial dose being high 
but then falling over subsequent days. While VA prescription records can 
capture this complexity when a prescription is entered , the feature is not used 
with consistency by prescribers; therefore it is often difficult to know exactly what 
the prescriber intended and it is not infrequent that the number of tablets 
dispensed is not the same as the number of days prescribed. For example, the 
prescriber could intend an eight day prescription comprised of: 20mg daily for 2 
days, 1 Omg daily for 2 days, 5mg daily for 2 days and 2.5mg daily for 2 days. 
While this might be recorded as such in the record, it might also be recorded only 
as 15 5mg tablets to be used over 8 days: the patient would take 4 tablets each 
of the first two days, 2 the next 2, 1 the next 2, and half a tablet on each of the 
last 2 days. We tried to account for some of this complexity as detailed below, 
but ultimately some assumptions needed to be made. 
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Methylprednisolone and prednisone 'dose packs' comprise 21 tablets of 4mg and 
5mg of each drug, respectively, meant to be taken over 6 days as: 6 tablets on 
day one, 5 tablets on day two, 4 tablets on day three, 3 tablets on day four, 2 
tablets on day five, and 1 tablet on day six. In VA prescription records a dose-
pack prescription can be recorded as a 1 day prescription, a 6 day prescription, a 
21 day prescription (because 21 tablets are dispensed), or (default) a 30 day 
prescription (the 'dose pack', however, is the clearly identifiable 'unit' of the 
prescription). It is often not clear whether prescribers mean for individual 
patients to take the 'pack' as intended by the manufacturer, or whether they are 
using a convenient package to prescribe 5mg tablets. We assumed that all 'dose 
pack' prescriptions were used as meant by the manufacturer and converted all 
prescriptions to 21 tablets for 6 days, with average daily dose of either 14mg 
methylprednisolone or 17.5mg prednisone. This could underestimate the length 
of these prescriptions; however the total dose of GC over the whole prescription 
would remain the same, and each prescription would still qualify as a burst. 
In cases where the number of tablets was an integer multiple of the days 
prescribed (e.g. 20 5mg tablets for 10 days, 30 10mg tablets for 10 days), we 
assumed the intended dose was the multiplier times the dose of the tablet (here 
2 X 5mg = 1 Omg daily for 1 0 days, 3 X 1 Omg = 30mg daily for 10 days). To save 
money VA will often have patients cut tablets in half, so where the number of 
tablets was half the number days prescribed (e.g. 3 1 Omg tablets for 6 days), we 
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assumed the intended dose was 0.5 times the tablet dose (here 0.5 X 1 Omg = 
5mg daily for 6 days). 
Where the number of tablets prescribed was smaller than the number of days 
prescribed (e.g. 7 tablets for 30 days) and did not meet the above criteria, we set 
the length of the prescription equal to the number of tablets (here 7 days instead 
of 30). As 30 days is often the default length of prescriptions for VA, 
prescriptions with this number of tablets were frequent (34.59% of all GC 
prescriptions) and the prescription length was often reset. Likewise in cases 
where the number of tablets was larger than the number of days and did not 
meet the above criteria (e.g. 8 tablets for 1 day), we set the length of the 
prescription to the number of tablets (here 8 days instead of 1 ). 
Taking into account these changes, average daily doses for each GC 
prescription were calculated as: (strength of the tablets in mg) X (number of 
tablets dispensed) -:- (prescription length in days). All doses and average daily 
doses were converted to prednisone equivalents (25mg cortisone = 20mg 
hydrocortisone= 4mg methylprednisolone= 5mg prednisone= 5mg prednisolone 
= 4mg triamcinolone= 0.75mg betamethasone = 0.75mg dexamethasone).26-29 
90 
Analysis 
We used the self-controlled case series method to examine whether the risk of 
GIB was greater while an individual took a Ge compared to times when they 
were not taking Ges. Specifically, we examined the period while each subject 
was taking the Ge, and the 28-day period after the subject stopped taking the 
Ge (Figure 3.1). 
Event-dependent exposure can create bias in sees studies (see the General 
lntroduction).30 To account for this we defined a 4 week 'risk' period prior to Ge 
exposure. This removes from the baseline risk period Ml cases that could have 
occurred at an artificially high rate because the subsequent Ge exposure 
sometimes resulted from the hospitalization. (This apparently elevated case rate 
is an artifact of the sees method; exposure sometimes occurs in the period after 
hospitalization because the hospitalization itself leads to Ge prescribing, 
presumably during and then after the hospitalization.) The 'risk ratio' during this 
period does not represent a 'causal' relation , and should not be interpreted as 
such. Also note that 'adjusting' for outcome-dependent exposure does not 
control for time-dependent confounding by indication; i.e. an illness for which 
Ges may be prescribed and which independently 'causes' GIB can still confound 
an apparent Ge-GIB relationship (see below). 
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Figure 3.1: Classification of follow-up time in a typical GIB case 
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We used SAS v. 9.1 (SAS Institute, Inc., Cary, NC) for all SCCS analyses. 
Poisson regression was used to calculate incidence rate ratios (IRRs). We used 
5 year bands of age (aside from the first which encompassed ages 18-25) to 
control for age effects. 
Sensitivity analyses 
We performed a number of additional analyses: First, we limited follow-up time 
to the 2 years before and after GC exposure to limit the effect of comorbidities 
that might vary over time. Second, we performed an analysis using a more 
specific definition of GIS: any of a code for gastric ulcer with 
hemorrhage/perforation (531.xx), duodenal ulcer with hemorrhage/perforation 
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(532.xx), or Gl bleeding (578.xx), combined with a code for upper Gl endoscopy 
(432.xx or 443.xx) at any position of the discharge summary.14·21 -25 
Finally, we repeated our main analysis in a cohort of patients who had used 
ciprofloxacin rather than glucocorticoids. Ciprofloxacin is used similarly to GCs in 
that it is often used infrequently and in short courses. Our rationale was that 
there is no known effect of this antibiotic on the occurrence of GIB and none is 
theorized to be present; therefore, if a 'causal' effect is apparent it might indicate 
that confounding by indication is present. In this case, confounding would 
probably occur because persons who use antibiotics are more likely to be ill in 
general, and therefore more likely to suffer GIB. This could also be the case with 
GCs. If the effects were similar, it could indicate that any observed relationship 
between GCs and GIB was indeed the effect of confounding. We formed our 
ciprofloxacin cohort using exactly the same definitions as in our GC cohort. 
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RESULTS 
The initial cohort of burst GC users comprised 627,306 subjects whose use of 
GCs exclusively met our definition of a GC burst. (Further details pertaining to 
the burst cohort are given in the appendix as are definitions for VA 'priorities'.) 
Of these, 1568 had a GIB. After excluding those with relevant hospitalizations 
and those whose events appeared to fall outside of their enrollment period, we 
were left with an analysis cohort of 481 persons (Figure 3.2). Of these, 93.8% 
were men, mean age (sd) was 65.3 years (12.3) (66.2 (11.8) for men, 52.9 (13.0) 
for women) . 72.8% were white, 13.9% African American, 4.6% black or white 
Hispanic, and 8. 7% other (Table 3.1 ). 
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Figure 3.2: Subject flow 
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Table 3.1: GIB case characteristics 
All Men Women 
N (%) 481 (100) 451 (93.8) 30 (6.2) 
Mean age at GIB (std) 65.3 (12.3) 66.2 (11.8) 52.9 (13.0) 
Race- N (%) 
White 350 (72.8) 326 (72.3) 24 (80.0) 
Black 67 (13.9) 64 (14.2) 3(10.0) 
Hispanic/AA 1 (0.2) 1 (0.2) 0 
Hispanic/white 21 (4.4) 21 (4.7) 0 
Asian 2 (0.4) 2 (0.4) 0 
Pacific Islander 1 (0.2) 1 (0.2) 0 
Unknown 39 (8.1) 36 (8.0) 3 (7.7) 
Priority- N (%) 
1 68(14.1) 62 (13.8) 6 (20.0) 
2 31 (6.4) 30 (6.7) 1 (3.3) 
3 64 (13.3) 59(13.1) 5 (16.7) 
4 2 (0.4) 0 2 (6.7) 
5 263 (54.7) 249 (55.2) 14 (46.7) 
6 4 (0.8) 4 (0.9) 0 
7 8 (1.7) 8 (1 .8) 0 
8 41 (8.5) 39 (8.7) 2 (6.7) 
No. of GC prescriptions 
mean (Q1 , Q3) 1 (1 ' 1) 1 (1 ' 1) 1 (1' 2) 
mean (sd) 1.4 (0.9) 1.4 (0.9) 1.4 (0.8) 
Most subjects received one burst GC prescription (76.9%) ; the median number 
was 1 (interquartile range 1 to 1) (Table 3.2). The average mean daily dose of 
GCs over the course of each burst in prednisone equivalents was 22.2 mg (sd = 
17.6). Prescribed GCs included prednisone (60.1% of prescriptions), 
methylprednisolone (32.4%) , dexamethasone (7.3%) , and hydrocortisone (0.3%) 
(Tables 3.3 and 3.4). 
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Table 3.2: GC prescription characteristics 
All Men Women 
Total number of burst GC 661 618 43 
prescriptions 
No. of GC prescriptions 
per person- N (%) 
1 370 (76.9) 348 (77 .2) 22 (73.3) 
2 74(15.4) 71 (15.7) 3 (1 0.0) 
3 26 (5.4) 21 (4.7) 5(16.7) 
4 1 (0.2) 1 (0.2) 0 
5 4 (0.8) 4 (0.9) 0 
6 3 (0.6) 3 (0.7) 0 
7 2 (0.4) 2 (0.4) 0 
8 0 0 0 
9 1 (0.2) 1 (0.2) 0 
GCs prescribed- N (%) 
prednisone 397 (60.1) 379 (61 .3) 18 (41.9) 
methylprednisolone 214 (32.4) 194 (31.4) 20 (46.5) 
dexamethasone 48 (7.3) 43 (7.0) 5 (11 .6) 
hydrocortisone 2 (0.3) 2 (0.3) 0 
Table 3.3: Mean and median lengths (days) of GC prescriptions 
Glucocorticoid All Men Women 
median (01, 03) 
mean (sd) 
all 6 (6, 10) 6 (6, 10) 6 (6, 10) 
8.9 (6.9) 9.0 (7.0) 7.9 (4.8) 
prednisone 8 (5, 12) 8(5, 12) 10 (6, 14) 
10.3 (7.4) 10.3 (7.6) 9.7 (3 .6) 
methylprednisolone 6 (6, 6) 6 (6, 6) 6 (6, 6) 
6.2 (1 .9) 2.3 (2.0) 5.9 (0.4) 
dexamethasone 4.5 (1 .0, 12.5) 4 (1 , 15) 5(1 , 10) 
9.5 (11 .1) 9.5 (11.2) 9.4(10.1) 
hydrocortisone 22.0 (14.0, 30.0) 22.0 (14.0, 30.0) 
22.0 (11 .3) 22.0 (11.3) 
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Table 3.4: Mean and median dose (mg) of GC prescriptions 
Glucocorticoid All Men Women 
median (Q1, Q3) 
mean (sd) 
all 17.5 (17.5, 25.0) 18.6 (17.5, 25.0) 17.5 (17.5, 21 .8) 
22.2 (17.6) 22.0 (17.3) 24.2 (21.1) 
prednisone 20.0 (17.5, 28.6) 20 (17.5, 12.0) 21 .0 (20, 36. 7) 
23.8 (16.1) 23.3(15.1) 32.8 (28.6) 
methylprednisolone 17.5(17.5, 17.5) 17.5 (17.5, 17.5) 17.5 (17.5, 17.5) 
17.0 (3.3) 17.0 (3.3) 16.5 (3.3) 
dexamethasone 26.7 (5.8, 26.7) 26.7 (6.7, 26.7) 5.0 (3.3, 60.0) 
33.3 (42.6) 34.3 (44.4) 22.8 (32.2) 
hydrocortisone 1.9 (1 .2, 2.5) 1.9 (1 .2, 2.5) 
1.9 (0.9) 1.9 (0.9) 
The risk of GIB during periods of GC use was 4 times the baseline risk (RI = 4.3, 
95% Cl = 2.3, 8.1) (Table 3.5). The risk of GIB in the 28 days after 
discontinuation of the GC was Rl = 2.3, 95% Cl = 1.5, 3.7. Note that the 28-day 
period prior to GC use should not be interpreted as the risk for GIB as the 
subjects in this group have not yet used GCs. It should simply be looked upon 
as a correction factor for event-dependent exposure. 
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Table 3.5: Main results of the sees analysis 
N 
baseline 
28-1 day prior to prescription 
taking GC 
days 1-28 after GC discontinuation 
Sensitivity analyses 
Number of cases of Relative 95% Cl 
GIB in risk period incidence 
481 
438 
14 
10 
19 
1 (ref) 
1.7 
4.3 
2.3 
1.0, 3.0 
2.3, 8.1 
1.5, 3.7 
Follow-up limited to 2 years before and after GC exposure 
Limiting the analysis to the 2 years around GC exposure so as to limit time-
varying confounders had little effect on the results though the number of cases in 
the exposure periods was very small (Table 3.6). 
Table 3.6: sees results using follow-up time 2 years around Ge exposure 
N 
baseline 
28-1 day prior to prescription 
taking GC 
days 1-28 after GC discontinuation 
More specific G/B definition 
Number of cases of Relative 95% Cl 
GIB in risk period incidence 
50 
43 
4 
3 
0 
1 (ref) 
3.4 
9.3 
1.2, 9.5 
2.8, 30.8 
When we limited our study cohort to those with the narrower GIB definition, we 
obtained results that were broadly similar to the main result (Table 3. 7). 
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Confidence intervals were wider reflecting the loss of power when using this 
more specific definition. 
Table 3.7: sees results using a narrower definition of GIB 
Number of cases of Relative 95% Cl 
GIB in risk period incidence 
N 
baseline 
28-1 day prior to prescription 
taking GC 
days 1-28 after GC discontinuation 
Ciprofloxacin comparison 
65 
58 
4 
3 
0 
1 (ref) 
3.9 
11.0 
1.4, 11.1 
3.3, 36.7 
The ciprofloxacin analysis showed a similar pattern of risk as the main analysis 
(Table 3.8). Note the larger IR in the 'pre-exposure' risk period. 
Table 3.8: sees result in the 'burst' ciprofloxacin cohort 
N 
baseline 
28-1 day prior to prescription 
taking GC 
days 1-28 after GC discontinuation 
Number of cases of Relative 
GIB in risk period incidence 
5272 
4812 
276 
50 
124 
100 
1 (ref) 
5.0 
3.4 
2.2 
95%CI 
4.4, 5.6 
2.6, 4.4 
1.9, 2.6 
DISCUSSION 
Interpretation 
Our analysis shows that GC use is associated with an elevated risk of GIB. We 
believe there are two possible interpretations of this result: 1) GC use is causally 
associated with GIB; 2) there is residual confounding that accounts for this 
apparent GC-GIB association. 
Our sensitivity analyses helped to sort out which of these two eventualities is 
more likely. Though there was little difference in the main effect measure in 
most of these analyses when compared to our main analysis, the fact that a 
similar effect was seen when using 'burst' ciprofloxacin as the exposure suggests 
that we may be observing uncontrolled confounding . This confounding, by 
definition, must be time-varying and could represent other medication use, other 
diseases, or other conditions such as general health status. Note that the 
relatively elevated Rl in the 'pre-exposure' risk period indicates a higher rate of 
ciprofloxacin prescribing after a hospitalization for GIB. It makes intuitive sense 
that persons who have been hospitalized for GIB may be prescribed antibiotics 
during their hospitalization and that this rate is likely to be above that of GC 
prescribing. 
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Results in context 
Whether GCs contribute to GIS has been somewhat controversial. Reports of 
GIS in persons with RA go back several decades, but though originally attributed 
to GCs, it is quite possible that the effect was in fact due to frequent co-
prescription with aspirin which is now a well recognized contributor to GIB?·8·10 A 
study from the Boston Collaborative Drug Surveillance Program was among the 
first to convincingly suggest that GCs could pose an independent risk.4 Later, 
despite a few studies suggesting that the risk of GIS was overblown, most 
studies continued to show a small elevation in risk of GIS associated with GC 
use (RRs of roughly 1.5-2.5).6·11 ·31 •32 Later studies suggested that there could be 
an interaction between GCs and NSAIDs resulting in significantly higher risk of 
GIB.7 Today, despite fairly convincing evidence, there are still physicians and 
investigators who do not believe that GCs are ulcerogenic. 9 Perhaps this is a 
result of a lower risk of bleeding when compared to NSAIDs. 
There has generally been little consideration of general health factors in these 
studies; i.e. persons in poor general health may be more likely to be prescribed 
GCs and more likely to have GIS independent of GC use. Additionally, few of 
these studies have examined whether short periods of GC use are dangerous. 
Hence, our study was designed to address these two issues. We hoped that the 
sees design would prove better in controlling for chronic and general health 
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factors, and would allow us to examine whether even short periods of GC could 
'trigger' GIB. 
Unfortunately we did not answer this question entirely satisfactorily. Our main 
results suggest that GC use is indeed a trigger for Gl bleeding; however, our final 
sensitivity analysis, using ciprofloxacin to examine whether there could be 
residual confounding since it should not contribute to an elevated GIB risk, 
suggests that there could indeed be additional time-dependent factors 
confounding a GC-GIB relationship. These likely represent either other acute 
illnesses or other health-related factors that we could not adjust for. 
Limitations 
The major limitation of this study is likely to be uncontrolled confounding ; indeed 
this may explain our results as discussed above. We feel that other potential 
sources of bias are less likely to be important. For instance there is unlikely to be 
outcome misclassification in this case-only study using well validated outcome 
definitions. It is true that there could be some exposure misclassification , indeed 
it may be likely given the many different ways GCs are prescribed and the 
number of prescriptions that we needed to modify; but it is difficult to know how 
this might have affected our results. It is also true that there could have been 
outside use of GCs and/or events that occurred outside of the VA. 
103 
Conclusion 
We have shown that it is possible that GC use can act as a trigger for GIB. 
However our sensitivity analysis using ciprofloxacin showed similar results to our 
main analysis and suggests that unmeasured, time-variable confounding might 
account for the apparent relationship. 
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APPENDIX 
BURST COHORT CHARACTERISTICS 
Subject characteristics 
Table a.1: Number of GC prescriptions per person in the GC burst cohort 
NumberofGC All persons Men Women 
burst N (%) N (%) N (%) 
prescriptions Total = 621,997 Total= 570,244 Total = 51,773 
per person persons (100%) persons (100%) persons (1 00%) 
1 475,870 (76.51) 437,178 (76.67) 38,702 (74.75) 
2 99,325 (15.97) 90,711 (15.91) 8,614 (16.64) 
3 29,054 (4.67) 26,339 (4.62) 2,715 (5.24) 
4 10,292 (1 .65) 9,301 (1 .63) 991 (1 .91) 
5 4,112 (0.66) 3,697 (0.65) 415 (0.80) 
6 1,706 (0.27) 1,533 (0.27) 173 (0.33) 
7 850 (0.14) 765 (0.13) 85 (0.16) 
8 389 (0.06) 355 (0.06) 34 (0.07) 
9 188 (0.03) 164 (0.03) 24 (0.05) 
10 109 (0.02) 100 (0.02) 9(0.01) 
11 55 (0.01) 49 (0.01) 6 (0.01) 
12 21 (0.00) 21 (0.00) 0 (0.00) 
13 9 (0.00) 7 (0.00) 2 (0.00) 
14 7 (0.00) 6 (0.00) 1 (0.00) 
15 6 (0.00) 4 (0.00) 2 (0.00) 
16 4 (0.00) 4 (0.00) 0 (0.00) 
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Table a.2: Birth decade of persons in the burst cohort 
Decade of Birth 
before 1910 
1910-1919 
1920-1929 
1930-1939 
1940-1949 
1950-1959 
1960-1969 
1970-1979 
1980-1989 
1990 or after 
All persons 
N (%) 
Total= 621,997 
persons (1 00%) 
5013 (0.81) 
17,669 (2.84) 
98,904 (15.90) 
116,439 (18.72) 
174,692 (28.090 
123,990 (19.93) 
53,201 (8.55) 
25,159 (4.04) 
6,915(1 .11) 
15 (0.00) 
Men 
N (%) 
Total = 570,244 
persons (100%) 
2,578 (0.45) 
17,205 (3.02) 
96,730 (16.96) 
113,757 (19.95) 
166,393 (29.18) 
107,365 (18.83) 
41,937 (7.35) 
18,972 (3.33) 
5,275 (0.93) 
12 (0.00) 
Table a.3: Race of persons in the burst cohort 
All persons Men 
N (%) N (%) 
Total= 621,997 Total= 570,244 
Race persons (100%) persons (1 00%) 
White 410,275 (65.96) 381,589 (66.92) 
Black 97,197 (15.63) 86,944 (15.25) 
Hispanic black 1 ,646 (0.26) 1 ,483 (0.26) 
Hispanic white 29,866 (4.80) 27,710 (4.86) 
Amerindian 3,284 (0.53) 2,956 (0.52) 
Asian 1,817 (0.29) 1 ,602 (0.28) 
Pacific Islander 4,729 (0.76) 4,181 (0. 75) 
Unknown 73,183 (11 .77) 63,658 (11 .16) 
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Women 
N (%) 
Total= 51,773 
persons (100%) 
2,435 (4.70) 
464 (0.09) 
2,174 (4.20) 
2,682 (18.72) 
8,299 (16.03) 
16,625 (32 .11) 
11 ,264 (21. 76) 
6,187(11 .95) 
1 ,640 (3.17) 
3 (0.01) 
Women 
N (%) 
Total = 51,773 
persons (1 00%) 
28,686 (55.41) 
10,253 (19.80) 
163 (9.90) 
2,156 (4.16) 
328 (0.63) 
215 (0.42) 
447 (0.86) 
9,525 (18.40) 
Table a.4: VA priority definitions 
Pvriol rity Description Notes 
a ue 
1 SC 50% or Veterans with service-connected disabilities rated 50 percent or 
higher more disabling. 
2 SC 30% or Veterans with service-connected conditions rated 30 to 40 
40% percent disabling. 
3 Other medical Veterans who are former POWs. 
4 
5 
6 
Vets Veterans awarded the Purple Heart. 
A&Aor 
disabled 
Pension 
No Co-Pay 
Vets 
Veterans with service-connected disabilities rated 10 to 29 
percent disabling. 
Veterans discharged from active duty for a disability incurred or 
aggravated in the line of duty. 
Veterans awarded special eligibility classification under 38 
U.S.C., Section 1151, "benefits for individuals disabled by 
treatment or vocational rehabilitation." 
Veterans who are receiving aid and attendance or housebound 
benefits. 
Veterans who have been determined by VA to be 
catastrophically disabled. 
Non-service-connected veterans and non-compensable service-
connected veterans rated 0 percent disabled whose annual 
income and net worth are below the established VA Means Test 
thresholds. 
Veterans receiving VA pension benefits. 
Veterans eligible for Medicaid benefits. 
All other eligible veterans who are not required to make co-
payments for their care, including: 
World War I veterans; 
Mexican Border War veterans; 
Veterans solely seeking care for disorders associated with: 
-exposure to herbicides while serving in Vietnam; 
- exposure to ionizing radiation during atmospheric 
testing or during the occupation of Hiroshima and 
Nagasaki; 
- disorders associated with service in the Gulf War; 
-any illness associated with service in combat in a war 
after the Gulf War or during a period of hostility after 
November 11, 1998. 
Compensable zero percent service-connected veterans. 
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Priority Description 
Value 
7 Below 
Means Test 
8 Others 
Notes 
7a =Non-compensable 0 percent service-connected veterans 
who were enrolled in the VA Health Care System on a specified 
date and who remained enrolled since that date. 
7c =Non-service-connected veterans who were enrolled in the 
VA Health Care System on a specified date and who have 
remained enrolled since that date. 
7e = Non-compensable 0 percent service-connected veterans 
not included in Sub priority a above. VA is not currently using 
sub priority e. 
7g = Non-service-connected veterans not included in Sub 
priority c above. VA is not currently using sub priority g. 
Sa = Non-compensable 0 percent service-connected veterans 
enrolled as of January 16, 2003 and who have remained 
enrolled since that date. 
8c = Non-service-connected veterans enrolled as of January 16, 
2003 and who have remained enrolled since that date. 
8e = Non-compensable 0 percent service-connected veterans 
applying for enrollment after January 16, 2003. 
8g = Non-service-connected veterans applying for enrollment 
after January 16, 2003. 
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Prescription characteristics 
Table a.5: Days supply of GC prescriptions 
All 
Glucocorticoid prescription 0-6.9 7-13.9 14-20.9 21-27.9 28-30 
mean (sd) lengths (0-30 days days days days days 
median (25%, 75%) days) 
All glucocorticoids 852,317 475,172 210,558 68,897 14,476 83,214 
(100%) (55.75%) (24.70%) (8.08%) (1 .70%) (9 .76%) 
betamethasone 26 16.8 (11 .0) (0.00%) 4 9 3 0 10 12.5 (7.0, 30.0) 
cortisone 94 22.4 (11 .0) (0.01%) 14 14 2 3 61 30.0 (1 0.0, 30.0) 
dexamethasone 51,433 11 .8 (11 .3) (6.03%) 25,745 8,242 4,025 692 12,729 6.0 (3.0, 25.0) 
hydrocortisone 1,552 24.3 (9 .9) (0.18%) 172 140 84 19 1,137 30.0 (20.0, 30.0) 
methylprednisolone 291 ,116 6.5 (3.4) (34.16%) 275,329 8,951 824 684 5,328 6.0 (6.0, 6.0) 
prednisolone 829 12.1 (9.4) (0.10%) 318 238 104 28 141 9.0 (5.0, 15.0) 
prednisone 507,243 11 .5 (8.3) (59.51%) 173,576 192,961 63,855 13,050 63,801 9.0 (6.0, 14.0) 
triamcinolone 24 13.1 (11.2) (0.00%) 14 3 0 0 7 6.0 (6.0, 30.0) 
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Table a.6: Number of tablets per prescriptions 
Glucocorticoid All < 10 10- 20-29.9 30-39.9 40-49.9 50-59.9 2: 60 
mean (sd) .. tabs 10.9 tabs tabs tabs tabs tabs median (25%, 75%) quantities tabs 
All glucocorticoids 758,252 207,596 373,987 80,719 32,510 14,806 48,634 
(100%) (27.38) (49.32) (10.65) (4.29) (1.95) (6.41) 
betamethasone 26 152 (102.6) (0.00%) 0 0 4 0 0 22 120.0 (118.0, 236.0) 
cortisone 83 44.0 (62.7) (0 .01%) 18 7 28 18 0 12 30 (13, 45) 
dexamethasone 44,047 37.7 (84.2) (5.81%) 22,474 3,765 7,434 1,789 700 7,885 12 (3.0, 30.0) 
hydrocortisone 1,430 40.0 (55.4) (0 .19%) 172 415 527 143 11 162 30.0 (30.0, 30.0) 
methylprednisolone 288,801 20.5 (6 .3) (38.09%) 12,809 273,470 1,169 681 146 526 21.0 (21.0, 21 .0) 
prednisolone 710 48.6 (60.4) (0.09) 145 100 141 64 75 185 30.0 (14.0 , 51 .0) 
prednisone 423,142 23.7 (26.4) (55.80) 171 ,973 96,230 71 ,408 29,815 13,874 39,842 19.0 (7 .0, 30.0) 
triamcinolone 13 10.2 (11 .3) (0.00) 5 0 8 0 0 0 16.0 (16.0, 33.5) 
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Table a.7: Average daily dose of drug over the course of each burst 
Glucocorticoid All < 10 10-10.9 20-29.9 30-39.9 40-49.9 50-59.9 60-69.9 70-79.9 80-89.9 90-99.9 i:!:: 100 
mean (SO) quantities mg/d mg/d mg/d mg/d mg/d mg/d mg/d mg/d mg/d mg/d mg/d 
median (25, 75) pred pred pred pred pred pred pred pred pred pred pred 
All glucocorticoids 95,610 403,199 232,940 65,557 16,885 14,266 3,779 1,978 3,126 628 14,349 
(11 .22) (47.31) 27.33 (7 .69) (1.98) (1 .67) (0.44) (0.23) (0.37) (0.07) (1 .68) 
betamethasone 26 52.9 (34.4) (0.00) 4 1 0 5 4 0 6 0 1 4 48.0 (32.0, 68.6) 
cortisone 94 8.9 (11 .2) (0.01) 80 4 1 5 3 0 0 1 0 0 0 5.0 (5.0 , 7.5) 
dexamethasone 51,433 39.6 (60.8) (6 .03) 12,025 4,217 22,808 1,274 1,740 1,186 914 283 2,185 115 4,686 26.7 (12.0, 26.7) 
hydrocortisone 1,552 6.0 (9.5) (0.18) 1,392 86 36 17 3 8 2 6 0 0 2 2.5 (2.5, 5.0) 
methylprednisolone 291 '116 17.8(15.1) (34.16) 15,496 269,377 2,179 489 1,610 58 45 26 276 4 1,556 17.5 (17.5, 17.5) 
prednisolone 829 43.8 (75.1) (0.10) 285 141 84 63 55 12 14 68 1 5 101 18.6 (5.0, 42.0) 
prednisone 507,243 23.6 (25.9) (59.51) 66,317 129,360 207,832 62,704 12,470 13,002 2,798 1,594 663 500 8,003 20.0 (15.0, 25.0) 
triamcinolone 24 9.9 (5.2) (0.00) 11 13 0 0 0 0 0 0 0 0 0 13.3 (5.0, 13.3) 
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